```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
 NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22   PATDPASPC - New patent database available
 NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18   New CAS Information Use Policies available online
 NEWS  17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  18 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus
 NEWS  19 MAY 23   GBFULL enhanced with patent drawing images
 NEWS  20 MAY 23   REGISTRY has been enhanced with source information from
                   CHEMCATS
 NEWS  21 MAY 26   STN User Update to be held June 6 and June 7 at the SLA 2005
                   Annual Conference
 NEWS  22 JUN 06   STN Patent Forums to be held in June 2005
 NEWS  23 JUN 06   The Analysis Edition of STN Express with Discover!
                   (Version 8.0 for Windows) now available

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:47:08 ON 13 JUN 2005

=> file reg
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:47:14 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 JUN 2005  HIGHEST RN 852100-26-6
DICTIONARY FILE UPDATES:  12 JUN 2005  HIGHEST RN 852100-26-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 10:50:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     16 TO ITERATE

100.0% PROCESSED      16 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           80 TO      560
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:50:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    315 TO ITERATE
```

```
100.0% PROCESSED     315 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

L3            2 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             163.48     163.69

FILE 'HCAPLUS' ENTERED AT 10:50:35 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Jun 2005  VOL 142 ISS 25
FILE LAST UPDATED: 12 Jun 2005  (20050612/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4            1 L3

=> d l4, ibib abs, 1

L4   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
Full Text  Citing References
ACCESSION NUMBER:         1999:511149  HCAPLUS
DOCUMENT NUMBER:          131:129825
TITLE:                    Novel antifungal compounds and process for producing
                          the same
INVENTOR(S):              Sakanaka, Osamu; Teraoka, Takeshi; Mitomo, Koichi;
                          Tamura, Takayoshi; Murai, Yasushi; Iinuma, Katsuharu;
                          Kuzuhara, Kikuko; Mikoshiba, Haruki; Taniguchi, Makoto
PATENT ASSIGNEE(S):       Meiji Seika Kaisha, Ltd., Japan
SOURCE:                   PCT Int. Appl., 92 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ----------------     ----   --------    ---------------------   --------
```

```
    WO 9940081           A1     19990812   WO 1999-JP541          19990208
        W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
            KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
            MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
            TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
            TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2319807           AA     19990812   CA 1999-2319807        19990208
    AU 9924398           A1     19990823   AU 1999-24398          19990208
    AU 751098            B2     20020808
    EP 1054011           A1     20001122   EP 1999-903901         19990208
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
    NZ 506249            A      20030429   NZ 1999-506249         19990208
PRIORITY APPLN. INFO.:                     JP 1998-26257        A 19980206
                                           WO 1999-JP541        W 19990208
OTHER SOURCE(S):         MARPAT 131:129825
GI
```



I

AB The title compds. [I; R1 = iso-Bu, tigloyl, isovaleryl, 2-methylbutanoyl; R2 = H, arom. acyl, protecting group such substituted benzoyl, substituted nicotinoyl; R3 = H, nitro, amino, acylamino, N,N-dialkylamino; with provisos] are prepd. Thus, UK-2A in CH2Cl2 contg. pyridine and PCl5 was refluxed for 1.5 h, the reaction mixt. was allowed to cool and then reacted with methanol for 15 h to give (2R,3R,4S,7S)-7-amino-2-benzyl-5,9-dioxa-3-isobutyryloxy-4-methyl-1,6-cyclononanedione. In an antifungal test, (2R,3R,4S,7S)-7-(2-hydroxynicotinylamino)-2-benzyl-5,9-dioxa-3-isobutyryl-4-methyl-1,6-cyclononanedione (also prepd.) at 0.05 µg showed potency almost double that of UK-2A against Saccharomyces cerevisiae.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file caold
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST                                     5.10    168.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE     TOTAL
                                                       ENTRY   SESSION
CA SUBSCRIBER PRICE                                    -0.73     -0.73
```

FILE 'CAOLD' ENTERED AT 10:50:48 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGlstRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 10:47:08 ON 13 JUN 2005)

     FILE 'REGISTRY' ENTERED AT 10:47:14 ON 13 JUN 2005
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            2 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 10:50:35 ON 13 JUN 2005
L4            1 S L3

     FILE 'CAOLD' ENTERED AT 10:50:48 ON 13 JUN 2005

=> s l3
L5          0 L3

=>
```

```
* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
NEWS  2           "Ask CAS" for self-help around the clock
NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                  (ROSPATENT) added to list of core patent offices covered
NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS  12 MAR 22   PATDPASPC - New patent database available
NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                  fields
NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
NEWS  16 APR 18   New CAS Information Use Policies available online
NEWS  17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
NEWS  18 APR 28   Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
NEWS  19 MAY 23   GBFULL enhanced with patent drawing images
NEWS  20 MAY 23   REGISTRY has been enhanced with source information from
                  CHEMCATS
NEWS  21 MAY 26   STN User Update to be held June 6 and June 7 at the SLA 2005
                  Annual Conference
NEWS  22 JUN 06   STN Patent Forums to be held in June 2005
NEWS  23 JUN 06   The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available

NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:09:42 ON 13 JUN 2005

=> file reg
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.84       0.84

FILE 'REGISTRY' ENTERED AT 10:12:14 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 JUN 2005  HIGHEST RN 852100-26-6
DICTIONARY FILE UPDATES:  12 JUN 2005  HIGHEST RN 852100-26-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Page 1-A
```



Page 1-C



Page 1-D



Page 2-A



Page 2-B



Page 2-C



Page 2-D



Page 3-B



Page 3-C



Page 3-D

```
VAR G1=23/24
REP G20=(1-2) 12-5 12-15
NODE ATTRIBUTES:
HCOUNT   IS M2      AT  12
HCOUNT   IS M1      AT  21
HCOUNT   IS M3      AT  23
HCOUNT   IS M2      AT  24
HCOUNT   IS E3      AT  25
NSPEC    IS R       AT   1
NSPEC    IS R       AT   2
NSPEC    IS R       AT   3
NSPEC    IS R       AT   4
NSPEC    IS R       AT   5
NSPEC    IS R       AT   6
NSPEC    IS R       AT   7
NSPEC    IS R       AT   8
NSPEC    IS R       AT   9
NSPEC    IS C       AT  10
NSPEC    IS C       AT  11
NSPEC    IS C       AT  12
NSPEC    IS R       AT  13
```

```
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS C      AT  21
NSPEC   IS C      AT  22
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  10 11 12 20 21 23 24 25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE


=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:12:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    342 TO ITERATE

100.0% PROCESSED     342 ITERATIONS                          322 ANSWERS
SEARCH TIME: 00.00.01

L2          322 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     162.17

FILE 'HCAPLUS' ENTERED AT 10:13:05 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Jun 2005  VOL 142 ISS 25
FILE LAST UPDATED: 12 Jun 2005  (20050612/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
```

```
=> s l2
L3            23 L2

=> s l3 and sakanaka, o?/au
             24 SAKANAKA, O?/AU
L4            3 L3 AND SAKANAKA, O?/AU

=> d l4, ibib abs hitstr, 1-3

L4   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 1999:511149 HCAPLUS
DOCUMENT NUMBER: 131:129825
TITLE: Novel antifungal compounds and process for producing the same
INVENTOR(S): **Sakanaka, Osamu**; Teraoka, Takeshi; Mitomo, Koichi; Tamura, Takayoshi; Murai, Yasushi; Iinuma, Katsuharu; Kuzuhara, Kikuko; Mikoshiba, Haruki; Taniguchi, Makoto
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9940081	A1	19990812	WO 1999-JP541		19990208
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2319807	AA	19990812	CA 1999-2319807		19990208
AU 9924398	A1	19990823	AU 1999-24398		19990208
AU 751098	B2	20020808			
EP 1054011	A1	20001122	EP 1999-903901		19990208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
NZ 506249	A	20030429	NZ 1999-506249		19990208
PRIORITY APPLN. INFO.:			JP 1998-26257	A	19980206
			WO 1999-JP541	W	19990208

OTHER SOURCE(S): MARPAT 131:129825
GI



I

AB The title compds. [I; R1 = iso-Bu, tigloyl, isovaleryl, 2-methylbutanoyl; R2 = H, arom. acyl, protecting group such substituted benzoyl, substituted nicotinoyl; R3 = H, nitro, amino, acylamino, N,N-dialkylamino; with provisos] are prepd. Thus, UK-2A in CH2Cl2 contg. pyridine and PCl5 was refluxed for 1.5 h, the reaction mixt. was allowed to cool and then reacted with methanol for 15 h to give (2R,3R,4S,7S)-7-amino-2-benzyl-5,9-dioxa-3-isobutyryloxy-4-methyl-1,6-cyclononanedione. In an antifungal test, (2R,3R,4S,7S)-7-(2-hydroxynicotinylamino)-2-benzyl-5,9-dioxa-3-isobutyryl-4-methyl-1,6-cyclononanedione (also prepd.) at 0.05 μg showed potency almost double that of UK-2A against Saccharomyces cerevisiae.

IT **234112-85-7P 234112-86-8P 234112-88-0P**
234112-89-1P 234112-90-4P 234113-05-4P
234113-06-5P 234113-14-5P 234113-15-6P
234113-16-7P 234113-17-8P 234113-21-4P
234113-26-9P 234113-27-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of UK-2A derivs. as antifungals)

RN 234112-85-7 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4,6-dimethoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-86-8 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4,5-dimethoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-88-0 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4,5-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-89-1 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-90-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-1-oxido-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-05-4 HCAPLUS

CN Heptanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-06-5 HCAPLUS

CN Decanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-14-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-nitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-15-6 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(3-amino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-16-7 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-5-nitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-17-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(5-amino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-21-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3,5-dinitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-26-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-8-[(4-nitrophenyl)methyl]-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-27-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[(4-aminophenyl)methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 210300-07-5P 215798-04-2P 215798-05-3P
234112-77-7P 234112-78-8P 234112-79-9P
234112-80-2P 234112-81-3P 234112-82-4P
234112-83-5P 234112-84-6P 234112-87-9P
234112-91-5P 234112-92-6P 234112-93-7P
234112-94-8P 234112-95-9P 234112-96-0P
234112-97-1P 234112-98-2P 234112-99-3P
234113-00-9P 234113-01-0P 234113-02-1P
234113-03-2P 234113-04-3P 234113-07-6P
234113-08-7P 234113-09-8P 234113-10-1P
234113-11-2P 234113-12-3P 234113-13-4P
234113-18-9P 234113-19-0P 234113-20-3P
234113-22-5P 234113-23-6P 234113-24-7P
234113-25-8P 234113-28-1P 234113-29-2P
234113-30-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of UK-2A derivs. as antifungals)
RN 210300-07-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-05-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 234112-77-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 210300-07-5
CMF C19 H25 N O6

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 234112-78-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-3-[[(phenylmethoxy)carbonyl]amino]-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-79-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-80-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,6-dihydro-6-oxo-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-81-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-8-(phenylmethyl)-3-[[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)carbonyl]amino]-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-82-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-methyl-4-quinolinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-83-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-3-oxo-2-quinoxalinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-84-6 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,6-dihydro-3-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-87-9 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4,6-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-91-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[6-(acetyloxy)-4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-92-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-6-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-93-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-94-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(benzoyloxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-95-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(1-methylethoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-96-0 HCAPLUS
CN Butanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-97-1 HCAPLUS
CN Butanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-98-2 HCAPLUS
CN Pentanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-99-3 HCAPLUS
CN Hexanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-00-9 HCAPLUS
CN Heptanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-01-0 HCAPLUS
CN Nonanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-02-1 HCAPLUS
CN Decanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-

pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-03-2 HCAPLUS
CN Pentanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-04-3 HCAPLUS
CN Hexanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-07-6 HCAPLUS
CN Pentanedioic acid, butyl 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-08-7 HCAPLUS
CN Heptanedioic acid, mono[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-09-8 HCAPLUS
CN Decanedioic acid, mono[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-10-1 HCAPLUS
CN Alanine, N-[(phenylmethoxy)carbonyl]-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-11-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-

[[bis(phenylmethoxy)phosphinyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-12-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(diethoxyphosphinyl)oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-13-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-18-9 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(4-chloro-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-19-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(5-chloro-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-20-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-4-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-22-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(dimethylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-23-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[5-(dimethylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-24-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(3,5-diamino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-25-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[5-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-28-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[[4-(formylamino)phenyl]methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-29-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[[4-(dimethylamino)phenyl]methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-30-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[1,6-dihydro-4-methoxy-6-oxo-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **167173-85-5**, (+)-UK-2A
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. as antifungals)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:184083 HCAPLUS
DOCUMENT NUMBER: 130:193104
TITLE: Rice blast controlling agents and wheat scab controlling agents
INVENTOR(S): Teraoka, Takeshi; Kuzuhara, Kikuko; Mikoshiba, Haruki; Matsumoto, Kuniomi; Iinuma, Katsuharu; Futamura, Takafumi; Yasutake, Tetsuya; **Sakanaka, Osamu**; Mitomo, Koichi; Taniguchi, Makoto
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911127	A1	19990311	WO 1998-JP3876	19980831
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9888878	A1	19990322	AU 1998-88878	19980831
EP 1013169	A1	20000628	EP 1998-940634	19980831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1997-233658 A 19970829
WO 1998-JP3876 W 19980831

OTHER SOURCE(S): MARPAT 130:193104
GI



AB These agents contain a compd. represented by formula (I) in which R1 represents alkyl or alkenyl and R2 represents hydrogen or methoxy. The compd. is highly effective in preventing rice blast and wheat scab and is not injurious to the plants. Specific compds. used in the examples are obtained by the method described in a publication presented earlier. Activities of I where R1 = iso-Pr and R2 = H (1), R1 = iso-Pr and R2 = OMe (2), R1 = (Z)-2-butenyl and R2 = OMe (3), R1 = iso-Bu and R2 = OMe (4), and R1 = sec-Bu and R2 = OMe (5), were demonstrated.

IT **167173-87-7 167173-88-8 220766-86-9 220766-87-0 220827-77-0**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(as rice blast controlling agents and wheat scab controlling agents)

RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS

CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 220766-86-9 HCAPLUS

CN Propanoic acid, 2-methyl-, 3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)



RN 220766-87-0 HCAPLUS

CN Propanoic acid, 2-methyl-, 3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)



RN 220827-77-0 HCAPLUS

CN 3-Pentenoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:19692 HCAPLUS
DOCUMENT NUMBER: 130:168617
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 III. Absolute configuration of an antifungal antibiotic, UK-2A, and consideration of its conformation
AUTHOR(S): Shibata, Kozo; Hanafi, Muhammad; Fujii, Jyunko; **Sakanaka, Osamu**; Iinuma, Katsuharu; Ueki, Masashi; Taniguchi, Makoto
CORPORATE SOURCE: Faculty of Science, Osaka City University, Osaka,

558-8585, Japan
SOURCE: Journal of Antibiotics (1998), 51(12), 1113-1116
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The abs. configuration of UK-2A (I) was detd. by the elucidation of the abs. configurations of butanolide II and the serine deriv. III, the products of alk. hydrolysis of I. The abs. configuration of UK-2A was found to be (+)-(2R,3R,4S,7S).

IT **167173-86-6**, UK 2B **167173-87-7**, UK 2C
167173-88-8, UK 2D
RL: MSC (Miscellaneous)
(detn. of the abs. configuration of UK-2A, an antifungal antibiotic)

RN 167173-86-6 HCAPLUS
CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



IT **167173-85-5**
RL: PRP (Properties)
(detn. of the abs. configuration of UK-2A, an antifungal antibiotic)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:09:42 ON 13 JUN 2005)

FILE 'REGISTRY' ENTERED AT 10:12:14 ON 13 JUN 2005
L1 STRUCTURE UPLOADED
L2 322 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 10:13:05 ON 13 JUN 2005
L3 23 S L2
L4 3 S L3 AND SAKANAKA, O?/AU

```
=> s l3 not 4
      5117530 4
L5          13 L3 NOT 4

=> s l3 not l4
L6          20 L3 NOT L4

=> s l6 and mitomo, k?/au
            42 MITOMO, K?/AU
L7           0 L6 AND MITOMO, K?/AU

=> s l6 and tamura, t?/au
          4967 TAMURA, T?/AU
L8           0 L6 AND TAMURA, T?/AU

=> s l6 and iinuma, k?/au
           366 IINUMA, K?/AU
L9           0 L6 AND IINUMA, K?/AU

=> s l6 and teraoka, t?/au
           367 TERAOKA, T?/AU
L10          0 L6 AND TERAOKA, T?/AU

=> s l6 and kuzuhara, k?/au
            61 KUZUHARA, K?/AU
L11          0 L6 AND KUZUHARA, K?/AU

=> s l6 and mikoshiba, h?/au
           138 MIKOSHIBA, H?/AU
L12          0 L6 AND MIKOSHIBA, H?/AU

=> s l6 and taniguchi, m?/au
          3612 TANIGUCHI, M?/AU
L13         11 L6 AND TANIGUCHI, M?/AU

=> d l13, ibib abs hitstr, 1-11

L13  ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2004:937345 HCAPLUS
DOCUMENT NUMBER: 142:348094
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 VI (3). Role of substituents on dilactone ring of UK-2A and antimycin A3 against generation of reactive oxygen species in porcine renal proximal tubule LLC-PK1 cells.
AUTHOR(S): Fujita, Ken-Ichi; Kiso, Tetsuo; Usuki, Yoshinosuke; Tanaka, Toshio; **Taniguchi, Makoto**
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2004), 57(10), 687-690
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The role of the substituents on the dilactone of UK-2A and antimycin A3 (AA) against reactive oxygen species (ROS) generation in porcine renal proximal tubule LLC-PK1 cells was studied. Results showed that AA and its

derivs. 4~7 stimulated ROS generation. They have a 3-formamidosalicylic moiety at the C7 position. The level of ROS generation induced by AA at 5 and 10 μM were the highest among the derivs. tested and 2.3-fold of the control. On the other hand, UK-2A and its derivs. 1~3, epi-1 and epi-2 did not greatly stimulate ROS generation. These results indicate that a 3-formamidosalicylic moiety contributes to ROS generation. In addn., the level of ROS generation among the derivs. correlated with the intensity of respiratory inhibition. The LLC-PK1 cells treated with the derivs. tested in this study showed morphologies similar to necrotic cell death under microscopic observation. However, it has been reported that AA induces the activation of caspases and DNA fragmentation, which are typical apoptotic responses.

IT **167173-85-5**, UK-2A **167173-87-7** **215798-04-2** **464157-53-7** **464157-56-0**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp.)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 464157-53-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464157-56-0 HCAPLUS
CN Butanoic acid, 3-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:508203 HCAPLUS
DOCUMENT NUMBER: 137:279002
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 VI (2). Structure-activity relationships of UK-2A
AUTHOR(S): Usuki, Yoshinosuke; Goto, Kimihiko; Kiso, Tetsuo; Tani, Kazunori; Ping, Xu; Fujita, Ken-Ichi; Iio, Hideo; **Taniguchi, Makoto**
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2002), 55(6), 607-610
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB UK-2A and antimycin A3 analogs, e.g. I, were tested for their respiratory inhibition in bovine heart SMP and their cytotoxic activity was measured against porcine renal proximal tubule cells. The structure activity relationship was examd. as well.

IT **167173-85-5**, UK-2A **167173-87-7** **215798-04-2** **464157-53-7** **464157-56-0**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(respiratory inhibition, cytotoxicity, and structure-activity relationships of UK-2A and antimycin A3 synthetic hybrids)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 464157-53-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464157-56-0 HCAPLUS
CN Butanoic acid, 3-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:262139 HCAPLUS
DOCUMENT NUMBER: 137:30441
TITLE: UK-2A, B, C, and D, novel antifungal antibiotics from Streptomyces sp. 517-02: VII. Membrane injury induced by C9-UK-2A, a derivative of UK-2A, in Rhodotorula mucilaginosa IFO 0001
AUTHOR(S): Tani, Kazunori; Usuki, Yoshinosuke; Motoba, Kazuhiko; Fujita, Ken-Ichi; **Taniguchi, Makoto**
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2002), 55(3), 315-321
CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB UK-2A is a potent antifungal antibiotic and its structure is highly similar to that of antimycin A3 (AA). UK-2A and AA inhibit mitochondrial electron transport at complex III. However, the antifungal activities of UK-2A and AA disappear after 48-h treatment. In an attempt to improve the duration of the antifungal activity of UK-2A, several UK-2A derivs. were prepd. by substituting its nine-membered dilactone ring with an n-alkyl or an isoprenyl moiety. Among all the derivs. tested, C9-UK-2A (I) and C10-UK-2A showed the most potent and durable antifungal activities against a strict aerobic yeast, Rhodotorula mucilaginosa IFO 0001. I, in particular, continued to demonstrate its broad-spectrum antifungal activity after 120-h treatment. Therefore, we focused on I to further examine its mode of action against the yeast. Interestingly, I did not inhibit cellular respiration of the cells even at concns. greater than 100 μg/mL. I gradually induced the efflux of potassium ions from the cells. Moreover, I gradually induced the release of glucose from glucose-encapsulating liposomes. The patterns of efflux and release induced by I were not as rapid as those seen with amphotericin B. These results suggest a membrane injury caused by I in R. mucilaginosa IFO 0001.

IT **167173-85-5**, UK-2A
RL: PAC (Pharmacological activity); BIOL (Biological study)
(activity of UK-2A and derivs. against Rhodotorula mucilaginosa)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:557166 HCAPLUS
DOCUMENT NUMBER: 135:300904
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. VI (1). Structure-activity relationships of UK-2A

AUTHOR(S): Usuki, Yoshinosuke; Tani, Kazunori; Fujita, Ken-Ichi; **Taniguchi, Makoto**
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2001), 54(7), 600-602
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of UK-2A analogs, where the nine-membered dilactone residue was replaced by several alkyl or isoprenyl moieties, and their biol. effects were studied. All the tested compds., such as UK-2A, AA, and their derivs., did not show any growth inhibitory activity against both Gram-neg. and Gram-pos. bacteria up to 100μg/mL. Salicylic acid moiety or pyridinecarboxylic acid moiety plus a hydrophobic structure is at least necessary for expression of antifungal action. The 9-membered dilactone ring moiety itself is not essential for the antimicrobial activity, and C8-alkyl group is flexible and hydrophobic that makes C8-UK-2A interact the binding domain to prevent yeasts and filamentous fungi from growing. The decrease in activity of isoprenylated UK-2A derivs. was due to a loss of flexibility, which interferes in their taking active conformations. AA had strong cytotoxicity against porcine renal proximal tubule LLC-PK1 cells and other types of cultured cells compared to UK-2A. The inhibitory of UK-2A and AA for the uncoupler stimulated respiration of bovine heart submitochondrial particles was examd. C8-3MeOSA showed comparably high inhibitory activity similar to C8-AA and AA, although its antimicrobial activities were weaker than those were. The mode of action of C8-UK-2A would be different from that of UK-2A.

IT **167173-85-5**, UK-2A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. VI (1). Structure-activity relationships of UK-2A)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:574605 HCAPLUS
DOCUMENT NUMBER: 131:297409
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 V. Inhibition mechanism of bovine heart mitochondrial cytochrome bc1 by the novel

antibiotic UK-2A

AUTHOR(S): Machida, Kiyotaka; Takimoto, Hiroaki; Miyoshi, Hideto; **Taniguchi, Makoto**

CORPORATE SOURCE: Department of Biology, Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan

SOURCE: Journal of Antibiotics (1999), 52(8), 748-753
CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB UK-2A is a potent antifungal antibiotic isolated from Streptomyces sp. 517-02 and its structure is highly similar to that of antimycin A. The authors investigated the inhibition mechanism of bovine heart mitochondrial cytochrome bc1 complex by the UK-2A using antimycin A and myxothiazol as the ref. inhibitors of ubiquinol oxidn. (Qo) and ubiquinone redn. (Qi) sites, resp. The inhibitory potency of UK-2A was about 3-fold less than antimycin A. On the basis of the effects of UK-2A on the redn. kinetics of b and c1 hemes, this compd. appeared to be an inhibitor of the Qi site. However, since spectral changes of dithionite-reduced cytochrome b induced by UK-2A binding differed from that of antimycin A, the precise binding manner of UK-2A to the enzyme is not identical to that of antimycin A. It could be concluded that antimycin A binding to cytochrome b is primarily decided by structural specificity of the salicylic acid moiety.

IT **167173-85-5**, Antibiotic UK-2A **167173-86-6**, Antibiotic UK-2B **167173-87-7**, Antibiotic UK-2C **167173-88-8**, Antibiotic UK-2D
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(UK-2A, B, C and D as novel antifungal antibiotics from Streptomyces)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Cited References

ACCESSION NUMBER: 1999:368241 HCAPLUS
DOCUMENT NUMBER: 131:125082
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02: IV. Comparative studies of UK-2A with antimycin A3 on cytotoxic activity and reactive oxygen species generation in LLC-PK1 cells
AUTHOR(S): Takimoto, Hiroaki; Machida, Kiyotaka; Ueki, Masashi; Tanaka, Toshio; **Taniguchi, Makoto**
CORPORATE SOURCE: Department of Biology, Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (1999), 52(5), 480-484
CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A, a novel antifungal antibiotic, is a structural relative of antimycin A3 (AA) and its mode of action is similar to that of AA which inhibits mitochondrial electron transport at complex III. In spite of their structural resemblance, AA had strong cytotoxicity while UK-2A had little cytotoxicity against LLC-PK1 cells as well as other types of cultured cells. When cells were treated with UK-2A or with AA the intracellular ATP content decreased significantly within 5 min in glucose-free medium to almost the same extent in both cases. Moreover, under the same conditions, UK-2A killed cells at a similar rate to AA. This suggested that UK-2A entered into the cells and, like AA, inhibited mitochondrial electron transport. On the other hand, AA stimulated reactive oxygen species (ROS) prodn. within 5 min even at a low concn. of 1 μM whereas UK-2A did not show such an effect. The difference in the ROS-producing abilities of UK-2A and AA may account for the different cytotoxic effects of the two compds.

IT **167173-85-5**, UK-2A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparative studies of UK-2A with antimycin A3 on cytotoxic activity and reactive oxygen species generation in LLC-PK1 cells)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1998:22846 HCAPLUS
DOCUMENT NUMBER: 128:163891
TITLE: The mode of action of UK-2A and UK-3A, novel antifungal antibiotics from Streptomyces sp. 517-02
AUTHOR(S): Ueki, Masashi; **Taniguchi, Makoto**
CORPORATE SOURCE: Dep. Biology, Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1997), 50(12), 1052-1057
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A and UK-3A are structural relatives of antimycins, which were isolated as antifungal antibiotics with little cytotoxicity that

demonstrated inhibition of respiratory activity. They halve the cellular respiration of yeast within 4~5 min and the intracellular ATP content within 2~5 min. They inhibited the yeast mitochondrial respiration using β-hydroxybutyrate and succinate as a respiratory substrate, but no inhibition was obsd. using ascorbate-reduced tetra-Me p-phenylenediamine as the substrate. The site of respiratory inhibition of UK-2A and UK-3A was thought to be the cytochrome bc1 complex in the mitochondrial electron transport chain of yeast cells. They also inhibited the mitochondrial respiration of rat liver. Intact animal cells might have some system to defend themselves from the actions of UK-2A and UK-3A.

IT **167173-85-5**, UK-2A **194931-82-3**, Antibiotic UK-3A
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(mechanism of antifungal action of UK-2A and UK-3A)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 194931-82-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:504110 HCAPLUS
DOCUMENT NUMBER: 127:217524
TITLE: UK-3A, a novel antifungal antibiotic from Streptomyces sp. 517-02: fermentation, isolation, structural elucidation and biological properties
AUTHOR(S): Ueki, Masashi; Kusumoto, Atsushi; Hanafi, Muhammad; Shibata, Kozo; Tanaka, Toshio; **Taniguchi, Makoto**
CORPORATE SOURCE: Faculty of Science, Osaka City University, Osaka, 558,

Japan
SOURCE: Journal of Antibiotics (1997), 50(7), 551-555
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A novel antifungal antibiotic, UK-3A (I), was obtained from the mycelial cake of Streptomyces sp. 517-02. I was very similar in structure to UK-2A, a structural relative of antimycin A. The antifungal spectrum of I was relatively broad (MICs for yeasts and filamentous fungi: 1.56~6.25 and 0.39~1.56 μg/mL, resp.). The cytotoxic activity of I was weak (IC50: 18~100 μg/mL).

IT **194931-82-3P**, Antibiotic UK 3A
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(UK-3A is a novel antifungal antibiotic from Streptomyces)

RN 194931-82-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:16443 HCAPLUS
DOCUMENT NUMBER: 126:144017
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. II. Structural elucidation
AUTHOR(S): Hanafi, Muhammad; Shibata, Kozo; Ueki, Masashi;

Taniguchi, Makoto
CORPORATE SOURCE: Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1996), 49(12), 1226-1231
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB UK-2A, UK-2B, UK-2C and UK-2D, novel antibiotics produced by Streptomyces sp. 517-02, exhibit strong antifungal activity. The structures were elucidated based on spectral and chem. evidence that these compds. are the derivs. of the nine-membered dilactone formed from serine and 4-hydroxypentanoic acid moiety.

IT **167173-86-6P** **167173-87-7P**, UK 2C **167173-88-8P**, UK 2D
RL: PRP (Properties); PUR (Purification or recovery); PREP (Preparation)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)

RN 167173-86-6 HCAPLUS
CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



IT **167173-85-5P**
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **186528-19-8P**, O-Methyl UK 2A
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)
RN 186528-19-8 HCAPLUS
CN Propanoic acid, 2-methyl-, 3-[[(3,4-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, [3S-(3R*,6R*,7S*,8S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:463922 HCAPLUS
DOCUMENT NUMBER: 125:109869
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. I. Fermentation, isolation,

and biological properties

AUTHOR(S): Ueki, Masahi; Abe, Keiichi; Hanafi, Muhammad; Shibata, Kozo; Tanaka, Toshio; **Taniguchi, Makoto**
CORPORATE SOURCE: Fac. Science, Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1996), 49(7), 639-643
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Novel antifungal antibiotics, UK-2A (I), UK-2B (II) and a mixt. of UK-2C and UK-2D, were obtained from the mycelial cake of Streptomyces sp. 517-02. All of the UK-2 compds. were similar in structure to antimycin A. The antifungal activities of of UK-2 compds. were as strong as that of antimycin A. However, the UK-2 compds. demonstrated weak cytotoxicity compared to antimycin A.

IT **167173-85-5**, UK 2A **167173-86-6**, UK 2B
167173-87-7, UK 2C **167173-88-8**, UK 2D
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. I. Fermn., isolation, and biol. properties)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS
CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



L13 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:934118 HCAPLUS
DOCUMENT NUMBER: 123:337552
TITLE: Fungicides manufacture with Streptoverticillium
INVENTOR(S): **Taniguchi, Makoto**; Shibata, Kozo; Abe, Keiichi; Kodama, Tooru; Uotani, Kazumichi; Oonishi, Yoshitaka
PATENT ASSIGNEE(S): Suntory Ltd., Japan; Meiji Seika Co.; Meiji Seika Kaisha, Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07233165	A2	19950905	JP 1994-26884	19940224
JP 3526602	B2	20040517		
PRIORITY APPLN. INFO.:			JP 1994-26884	19940224
OTHER SOURCE(S):	MARPAT 123:337552			

GI



I

AB Fungicides (I: R = linear or branched aliph. (un)satd. acyl group) are manufd. by culturing Streptoverticillium sp. SAM2084. Shake-culture of Streptoverticillium sp. SAM2084 for manuf. of four I wherein R = 2-methylpropanoyl (UK-2A), trans-2-methyl-2-butenoyl (UK-2B), 3-methylbutanoyl (UK-2C), and 2-methylbutanoyl (UK-2D) was shown. Also given were the physiol. and morphol. characteristics of the Streptoverticillium sp. SAM2084.

IT **167173-85-5P**, UK 2A **167173-86-6P**, UK 2B
167173-87-7P, UK 2C **167173-88-8P**, UK 2D
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fungicides manuf. with Streptoverticillium)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



=>

```
* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
NEWS  2           "Ask CAS" for self-help around the clock
NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                  (ROSPATENT) added to list of core patent offices covered
NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS  12 MAR 22   PATDPASPC - New patent database available
NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                  fields
NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
NEWS  16 APR 18   New CAS Information Use Policies available online
NEWS  17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
NEWS  18 APR 28   Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
NEWS  19 MAY 23   GBFULL enhanced with patent drawing images
NEWS  20 MAY 23   REGISTRY has been enhanced with source information from
                  CHEMCATS
NEWS  21 MAY 26   STN User Update to be held June 6 and June 7 at the SLA 2005
                  Annual Conference
NEWS  22 JUN 06   STN Patent Forums to be held in June 2005
NEWS  23 JUN 06   The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available

NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:46:59 ON 13 JUN 2005

=> file reg
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:47:05 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 JUN 2005  HIGHEST RN 852100-26-6
DICTIONARY FILE UPDATES:  12 JUN 2005  HIGHEST RN 852100-26-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 09:48:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:48:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      0 TO ITERATE
```

```
100.0% PROCESSED       0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L3             0 SEA SSS FUL L1

=>
L4       STRUCTURE UPLOADED

=> s l4
SAMPLE SEARCH INITIATED 09:53:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     18 TO ITERATE

100.0% PROCESSED      18 ITERATIONS                               16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          106 TO      614
PROJECTED ANSWERS:              80 TO      560

L5            16 SEA SSS SAM L4

=> s l4 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:53:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    342 TO ITERATE

100.0% PROCESSED     342 ITERATIONS                              322 ANSWERS
SEARCH TIME: 00.00.01

L6           322 SEA SSS FUL L4

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              326.10     326.31

FILE 'HCAPLUS' ENTERED AT 09:53:19 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Jun 2005  VOL 142 ISS 25
FILE LAST UPDATED: 12 Jun 2005  (20050612/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
L7 23 L6

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 2.45 328.76

FILE 'REGISTRY' ENTERED AT 09:53:26 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUN 2005 HIGHEST RN 852100-26-6
DICTIONARY FILE UPDATES: 12 JUN 2005 HIGHEST RN 852100-26-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.43 329.19

FILE 'HCAPLUS' ENTERED AT 09:53:35 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 13 Jun 2005 VOL 142 ISS 25
FILE LAST UPDATED: 12 Jun 2005 (20050612/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 09:46:59 ON 13 JUN 2005)

FILE 'REGISTRY' ENTERED AT 09:47:05 ON 13 JUN 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 16 S L4
L6 322 S L4 FULL

FILE 'HCAPLUS' ENTERED AT 09:53:19 ON 13 JUN 2005
L7 23 S L6

FILE 'REGISTRY' ENTERED AT 09:53:26 ON 13 JUN 2005

FILE 'HCAPLUS' ENTERED AT 09:53:35 ON 13 JUN 2005

=> d l7, ibib abs hitstr, 1-23

L7 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:937345 HCAPLUS
DOCUMENT NUMBER: 142:348094
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 VI (3). Role of substituents on dilactone ring of UK-2A and antimycin A3 against generation of reactive oxygen species in porcine renal proximal tubule LLC-PK1 cells.
AUTHOR(S): Fujita, Ken-Ichi; Kiso, Tetsuo; Usuki, Yoshinosuke; Tanaka, Toshio; Taniguchi, Makoto
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2004), 57(10), 687-690
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The role of the substituents on the dilactone of UK-2A and antimycin A3 (AA) against reactive oxygen species (ROS) generation in porcine renal proximal tubule LLC-PK1 cells was studied. Results showed that AA and its derivs. 4~7 stimulated ROS generation. They have a 3-formamidosalicylic moiety at the C7 position. The level of ROS generation induced by AA at 5 and 10 μM were the highest among the derivs. tested and 2.3-fold of the

control. On the other hand, UK-2A and its derivs. 1~3, epi-1 and epi-2 did not greatly stimulate ROS generation. These results indicate that a 3-formamidosalicylic moiety contributes to ROS generation. In addn., the level of ROS generation among the derivs. correlated with the intensity of respiratory inhibition. The LLC-PK1 cells treated with the derivs. tested in this study showed morphologies similar to necrotic cell death under microscopic observation. However, it has been reported that AA induces the activation of caspases and DNA fragmentation, which are typical apoptotic responses.

IT **167173-85-5**, UK-2A **167173-87-7** **215798-04-2** **464157-53-7** **464157-56-0**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp.)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 464157-53-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464157-56-0 HCAPLUS
CN Butanoic acid, 3-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:335078 HCAPLUS
DOCUMENT NUMBER: 138:337882
TITLE: Preparation of UK-2A derivatives as agricultural fungicides
INVENTOR(S): Meyer, Kevin Gerald; Rogers, Richard Brewer; Yao, Chenglin; Niyaz, Normohammed Mohamed; Adamski Butz, Jenifer Lynn; Nader, Bassam Salim
PATENT ASSIGNEE(S): Dow AgroSciences, LLC, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003035617	A2	20030501	WO 2002-US33947		20021023
WO 2003035617	A3	20031113			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2458974	AA	20030501	CA 2002-2458974		20021023
EP 1438306	A2	20040721	EP 2002-802199		20021023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005507921	T2	20050324	JP 2003-538133		20021023
US 2004192924	A1	20040930	US 2004-493456		20040423
US 6861390	B2	20050301			
PRIORITY APPLN. INFO.:			US 2001-335814P	P	20011023
			WO 2002-US33947	W	20021023

OTHER SOURCE(S): MARPAT 138:337882

GI



AB Derivs. of UK-2A of formula I [Z = H, alkoxy, acyl, OC(O)Oalkyl, OC(O)dialkylamino, etc.; Q, M = H, Me, Et, CF3, Ph, vinyl, cyclopropyl; T = O, OC(O), OCO2, S, SC(O), SCO2; G = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl] are provided for the treatment of plant fungal diseases. Thus, II was prepd. from UK-2A. The prepd. compds. were tested for control of in vivo whole plant fungal infection.

IT **512192-31-3P 512192-33-5P 512192-36-8P**
517875-15-9P 517875-16-0P 517875-17-1P
517875-18-2P 517875-19-3P 517875-20-6P

517875-21-7P 517875-22-8P 517875-23-9P
517875-24-0P 517875-25-1P 517875-26-2P
517875-27-3P 517875-28-4P 517875-29-5P
517875-30-8P 517875-31-9P 517875-32-0P
517875-33-1P 517875-34-2P 517875-35-3P
517875-36-4P 517875-37-5P 517875-38-6P
517875-39-7P 517875-40-0P 517875-41-1P
517875-42-2P 517875-43-3P 517875-44-4P
517875-45-5P 517875-46-6P 517875-47-7P
517875-48-8P 517875-49-9P 517875-50-2P
517875-51-3P 517875-52-4P 517875-53-5P
517875-54-6P 517875-55-7P 517875-56-8P
517875-57-9P 517875-58-0P 517875-59-1P
517875-60-4P 517875-61-5P 517875-62-6P
517875-63-7P 517875-64-8P 517875-65-9P
517875-66-0P 517875-67-1P 517875-68-2P
517875-69-3P 517875-70-6P 517875-71-7P
517875-72-8P 517875-73-9P 517875-74-0P
517875-76-2P 517875-79-5P 517875-80-8P
517875-81-9P 517875-82-0P 517875-83-1P
517875-84-2P 517875-85-3P 517875-86-4P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of UK-2A derivs. as agricultural fungicides)

RN 512192-31-3 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-2-propenyl)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-33-5 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-36-8 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-15-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(methoxymethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-16-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(ethoxymethoxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-17-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(propoxymethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-18-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(1-methylethoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-19-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(1,1-dimethylethoxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-20-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(2-methylpropoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-21-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(phenylmethoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-

(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-22-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(2-methoxyethoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-23-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(2-methoxy-1-methylethoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-24-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[2-(trimethylsilyl)ethoxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-25-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(2-chloroethoxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-26-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(2-cyanoethoxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-27-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(1-methoxyethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-28-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[2-(acetyloxy)ethoxy]methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-

4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-29-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(methylthio)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-30-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(phenylthio)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-31-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-32-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(1-oxopropoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-33-1 HCAPLUS
CN Butanoic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-34-2 HCAPLUS
CN Propanoic acid, 2-methyl-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-35-3 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-

yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-36-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[1-(acetyloxy)ethoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-37-5 HCAPLUS

CN Cyclopropanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-38-6 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(3-methoxy-1-oxopropoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-39-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(3-ethoxy-1-oxopropoxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-40-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(benzoyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-41-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(methoxyacetyl)oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-42-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(ethoxyacetyl)oxy]methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-

methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-43-3 HCAPLUS

CN Butanedioic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-44-4 HCAPLUS

CN Cyclopentanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-45-5 HCAPLUS

CN 2-Furancarboxylic acid, tetrahydro-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-46-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(propoxyacetyl)oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-47-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(1-methylethoxy)acetyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-48-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(butoxyacetyl)oxy]methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-49-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(2-methylpropoxy)acetyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-50-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(1-methylpropoxy)acetyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-51-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(2-methoxyethoxy)acetyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-52-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[[(cyclopentyloxy)acetyl]oxy]methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-53-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(phenoxyacetyl)oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-54-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(1,3-dihydro-3-oxo-1-isobenzofuranyl)oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-55-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(methoxycarbonyl)oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-56-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(ethoxycarbonyl)oxy]methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-57-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(propoxycarbonyl)oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-58-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-59-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(2-

methoxyethoxy)carbonyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-60-4 HCAPLUS

CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-N-[(3S,7R,8R,9S)-8-(cyclopentyloxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-61-5 HCAPLUS

CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-62-6 HCAPLUS

CN Propanoic acid, 3-methoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-63-7 HCAPLUS

CN Propanoic acid, 3-methoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-64-8 HCAPLUS

CN Cyclopropanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-65-9 HCAPLUS

CN Carbonic acid, 2-methoxyethyl [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-66-0 HCAPLUS

CN Acetic acid, methoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-67-1 HCAPLUS

CN Acetic acid, ethoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-68-2 HCAPLUS

CN Acetic acid, ethoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-69-3 HCAPLUS

CN Cyclopentanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-70-6 HCAPLUS

CN Cyclopentanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-71-7 HCAPLUS

CN Butanoic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-72-8 HCAPLUS

CN Butanoic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-73-9 HCAPLUS
CN 2-Pyridinecarboxamide, 4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-[(2-methylpropoxy)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-74-0 HCAPLUS
CN Propanoic acid, 2-(2-methoxyethoxy)-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-76-2 HCAPLUS
CN Propanoic acid, 2-methoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-79-5 HCAPLUS
CN Propanoic acid, 2-ethoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-

yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-80-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(1-oxo-2-propoxypropoxy)methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-81-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[(2,2,2-trifluoroethoxy)acetyl]oxy]methoxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-82-0 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-8-methoxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-83-1 HCAPLUS
CN Acetic acid, ethoxy-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-[(methylthio)methoxy]-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-84-2 HCAPLUS
CN Cyclopentanecarboxylic acid, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-[(methylthio)methoxy]-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-85-3 HCAPLUS
CN Acetic acid, (2-methoxyethoxy)-, [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-[(methylthio)methoxy]-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-86-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(3-oxo-2,5,8,11-tetraoxadodec-1-yl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 167173-85-5, UK-2A 321599-50-2 512192-35-7
512192-37-9 517875-87-5 517875-88-6
517875-89-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. as agricultural fungicides)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321599-50-2 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-35-7 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-37-9 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-87-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-(cyclopentyloxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-88-6 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-[(2-methyl-2-propenyl)oxy]-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-89-7 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-8-methoxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **321599-49-9P** **517875-14-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. as agricultural fungicides)
RN 321599-49-9 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-14-8 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-[(methylthio)methoxy]-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:301046 HCAPLUS
DOCUMENT NUMBER: 138:321054
TITLE: Process to produce alkyl-ether derivatives of UK-2A
INVENTOR(S): Niyaz, Normohammed Mohamed; Deamicis, Carl Vincent; Rogers, Richard Brewer; Meyer, Kevin Gerald; Dent, William Hunter, III; Anzeveno, Peter Biagio
PATENT ASSIGNEE(S): Dow Agrosciences LLC, USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031403	A2	20030417	WO 2002-US31848	20021004
WO 2003031403	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004186296	A1	20040923	US 2004-491978	20040405
US 6903219	B2	20050607		

PRIORITY APPLN. INFO.:			
US 2001-327547P	P	20011005	
WO 2002-US31848	W	20021004	

OTHER SOURCE(S): MARPAT 138:321054
GI



AB A process is disclosed for the prepn. of allyl-alkyl ether derivs. I [Y = H, benzyl, Si(alkyl)3, etc.; R3 = H, alk(en/yn)yl, cycloalkyl, (hetero)aryl] of antibiotic UK-2A. The process is comprised of coupling II with III [E = O, NR6; R4, R6 = alkyl, aryl] in the presence of a catalyst complex and solvent. For instance II [Y = PhCH2] was coupled to Et methallylcarbonate (dppf, Pd2dba3) to give the corresponding methallyl deriv. of I. Several examples are provided and subsequent sidechain redn. is also described.

IT **167173-85-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(palladium catalyzed allylation process to produce alkyl-ether derivs. of UK-2A)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **321599-49-9P 496781-72-7P 512192-28-8P 512192-29-9P 512192-30-2P 512192-31-3P 512192-32-4P 512192-33-5P 512192-34-6P 512192-35-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(palladium catalyzed allylation process to produce alkyl-ether derivs. of UK-2A)

RN 321599-49-9 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496781-72-7 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-28-8 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-29-9 HCAPLUS
CN 2-Pyridinecarboxamide, 3-(acetyloxy)-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-30-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-2-propenyl)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-31-3 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-2-propenyl)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-32-4 HCAPLUS
CN 2-Pyridinecarboxamide, 4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-33-5 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-34-6 HCAPLUS
CN 2-Pyridinecarboxamide, 3-(acetyloxy)-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-35-7 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-(2-propenyloxy)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **321599-50-2P 512192-36-8P 512192-37-9P 512192-38-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(palladium catalyzed allylation process to produce alkyl-ether derivs. of UK-2A)

RN 321599-50-2 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-36-8 HCAPLUS
CN 2-Pyridinecarboxamide, 3-[(acetyloxy)methoxy]-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-37-9 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512192-38-0 HCAPLUS
CN 2-Pyridinecarboxamide, 3-(acetyloxy)-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-2,6-dioxo-7-(phenylmethyl)-8-propoxy-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:117821 HCAPLUS
DOCUMENT NUMBER: 138:153370
TITLE: Preparation of UK-2A derivatives via reductive cleavage of the exocyclic ester of UK-2A or its derivatives
INVENTOR(S): Meyer, Kevin Gerald; Niyaz, Normohammed Mohamed; Deamicis, Carl Vincent; Rogers, Richard Brewer
PATENT ASSIGNEE(S): Dow Agrosciences LLC, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003011857	A1	20030213	WO 2002-US24204		20020731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2453577	AA	20030213	CA 2002-2453577		20020731
EP 1412351	A1	20040428	EP 2002-756820		20020731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011534	A	20040713	BR 2002-11534		20020731
JP 2005501836	T2	20050120	JP 2003-517049		20020731
US 2004171838	A1	20040902	US 2004-483947		20040115
PRIORITY APPLN. INFO.:			US 2001-308939P	P	20010731
			WO 2002-US24204	W	20020731

OTHER SOURCE(S): CASREACT 138:153370; MARPAT 138:153370
GI



I

AB The present invention discloses a process for the prepn. of UK-2A derivs., such as I [R = H; Y = H, (un)substituted benzyl, CH2OC1-8 alkyl, CH2OC3-8 cycloalkyl, allyl, (un)substituted tetrahydropyranyl, (un)substituted tetrahydrofuranyl, Si(C1-4 alkyl)3, and Si(Ph)x(C1-4 alkyl)3-x where x = 1-3], via reductive cleavage of the exocyclic ester of UK-2A I [R = OCOCH(Me)2; Y = H (II)] or its derivs., such as I [R = COCH(Me)2; Y = H,

(un)substituted benzyl, CH2OC1-8 alkyl, CH2OC3-8 cycloalkyl, allyl, (un)substituted tetrahydropyranyl, (un)substituted tetrahydrofuranyl, Si(C1-4 alkyl)3, and Si(Ph)x(C1-4 alkyl)3-x where x = 1-3], in the presence of a reducing agent and in the presence of an aprotic solvent. Thus, II was reacted with benzyl bromide to afford O-benzylated deriv. I [R = OCOCH(Me)2; Y = CH2Ph], which was treated with diisobutylaluminum hydride to afford UK-2A deriv. I [R = H; Y = CH2Ph].

IT **234112-89-1P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. via reductive cleavage of the exocyclic ester of UK-2A or its derivs.)

RN 234112-89-1 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **321599-49-9P 496781-72-7P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of UK-2A derivs. via reductive cleavage of the exocyclic ester of UK-2A or its derivs.)

RN 321599-49-9 HCAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496781-72-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 167173-85-5, UK-2A
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. via reductive cleavage of the exocyclic ester of UK-2A or its derivs.)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:508203 HCAPLUS
DOCUMENT NUMBER: 137:279002
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 VI (2). Structure-activity relationships of UK-2A
AUTHOR(S): Usuki, Yoshinosuke; Goto, Kimihiko; Kiso, Tetsuo; Tani, Kazunori; Ping, Xu; Fujita, Ken-Ichi; Iio, Hideo; Taniguchi, Makoto
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2002), 55(6), 607-610
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB UK-2A and antimycin A3 analogs, e.g. I, were tested for their respiratory inhibition in bovine heart SMP and their cytotoxic activity was measured against porcine renal proximal tubule cells. The structure activity relationship was examd. as well.

IT **167173-85-5**, UK-2A **167173-87-7** **215798-04-2** **464157-53-7** **464157-56-0**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(respiratory inhibition, cytotoxicity, and structure-activity relationships of UK-2A and antimycin A3 synthetic hybrids)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 464157-53-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-

hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464157-56-0 HCAPLUS
CN Butanoic acid, 3-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:262139 HCAPLUS
DOCUMENT NUMBER: 137:30441
TITLE: UK-2A, B, C, and D, novel antifungal antibiotics from Streptomyces sp. 517-02: VII. Membrane injury induced by C9-UK-2A, a derivative of UK-2A, in Rhodotorula mucilaginosa IFO 0001
AUTHOR(S): Tani, Kazunori; Usuki, Yoshinosuke; Motoba, Kazuhiko; Fujita, Ken-Ichi; Taniguchi, Makoto
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2002), 55(3), 315-321
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB UK-2A is a potent antifungal antibiotic and its structure is highly similar to that of antimycin A3 (AA). UK-2A and AA inhibit mitochondrial electron transport at complex III. However, the antifungal activities of UK-2A and AA disappear after 48-h treatment. In an attempt to improve the duration of the antifungal activity of UK-2A, several UK-2A derivs. were prepd. by substituting its nine-membered dilactone ring with an n-alkyl or an isoprenyl moiety. Among all the derivs. tested, C9-UK-2A (I) and C10-UK-2A showed the most potent and durable antifungal activities against a strict aerobic yeast, Rhodotorula mucilaginosa IFO 0001. I, in particular, continued to demonstrate its broad-spectrum antifungal activity after 120-h treatment. Therefore, we focused on I to further examine its mode of action against the yeast. Interestingly, I did not inhibit cellular respiration of the cells even at concns. greater than 100 μg/mL. I gradually induced the efflux of potassium ions from the cells. Moreover, I gradually induced the release of glucose from glucose-encapsulating liposomes. The patterns of efflux and release induced by I were not as rapid as those seen with amphotericin B. These results suggest a membrane injury caused by I in R. mucilaginosa IFO 0001.

IT **167173-85-5**, UK-2A
RL: PAC (Pharmacological activity); BIOL (Biological study)
(activity of UK-2A and derivs. against Rhodotorula mucilaginosa)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:557166 HCAPLUS
DOCUMENT NUMBER: 135:300904
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. VI (1). Structure-activity relationships of UK-2A
AUTHOR(S): Usuki, Yoshinosuke; Tani, Kazunori; Fujita, Ken-Ichi; Taniguchi, Makoto
CORPORATE SOURCE: Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (2001), 54(7), 600-602
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of UK-2A analogs, where the nine-membered dilactone residue was replaced by several alkyl or isoprenyl moieties, and their biol. effects were studied. All the tested compds., such as UK-2A, AA, and

their derivs., did not show any growth inhibitory activity against both Gram-neg. and Gram-pos. bacteria up to 100μg/mL. Salicylic acid moiety or pyridinecarboxylic acid moiety plus a hydrophobic structure is at least necessary for expression of antifungal action. The 9-membered dilactone ring moiety itself is not essential for the antimicrobial activity, and C8-alkyl group is flexible and hydrophobic that makes C8-UK-2A interact the binding domain to prevent yeasts and filamentous fungi from growing. The decrease in activity of isoprenylated UK-2A derivs. was due to a loss of flexibility, which interferes in their taking active conformations. AA had strong cytotoxicity against porcine renal proximal tubule LLC-PK1 cells and other types of cultured cells compared to UK-2A. The inhibitory of UK-2A and AA for the uncoupler stimulated respiration of bovine heart submitochondrial particles was examd. C8-3MeOSA showed comparably high inhibitory activity similar to C8-AA and AA, although its antimicrobial activities were weaker than those were. The mode of action of C8-UK-2A would be different from that of UK-2A.

IT **167173-85-5**, UK-2A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. VI (1). Structure-activity relationships of UK-2A)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:152650 HCAPLUS
DOCUMENT NUMBER: 134:207831
TITLE: Preparation, composition and use of heterocyclic aromatic amides as fungicides
INVENTOR(S): Ricks, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassam Salim; Miesel, John Louis; Fitzpatrick, Gina Marie; Meyer, Kevin Gerald; Niyaz, Noormohamed Mohamed; Morrison, Irene Mae; Henry, Matthew James; Adamski, Butz Jenifer Lynn; Gajewski, Robert Peter
PATENT ASSIGNEE(S): Dow Agrosciences LLC, USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
    WO 2001014339          A2    20010301    WO 2000-US21523          20000804
    WO 2001014339          A3    20011115
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
            MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
            AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US 6521622             B1    20030218    US 2000-620662           20000720
    CA 2376275             AA    20010301    CA 2000-2376275          20000804
    AU 2000065267          A5    20010319    AU 2000-65267            20000804
    AU 778108              B2    20041118
    US 6355660             B1    20020312    US 2000-632930           20000804
    EP 1204643             A2    20020515    EP 2000-952599           20000804
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    EP 1234823             A2    20020828    EP 2002-9583             20000804
    EP 1234823             A3    20030618
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    EP 1234824             A1    20020828    EP 2002-9584             20000804
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    EP 1234825             A2    20020828    EP 2002-9585             20000804
    EP 1234825             A3    20030618
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    EP 1234826             A2    20020828    EP 2002-9586             20000804
    EP 1234826             A3    20030618
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    EP 1234827             A2    20020828    EP 2002-9590             20000804
    EP 1234827             A3    20030618
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    TR 200200409           T2    20030321    TR 2002-200200409        20000804
    BR 2000013469          A     20030429    BR 2000-13469            20000804
    JP 2003527324          T2    20030916    JP 2001-518428           20000804
    EP 1486489             A2    20041215    EP 2004-22082            20000804
    EP 1486489             A3    20050511
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
    EP 1493733             A2    20050105    EP 2004-22081            20000804
    EP 1493733             A3    20050126
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
    US 2002177578          A1    20021128    US 2001-22413            20011213
    US 2003018052          A1    20030123    US 2001-22207            20011213
    US 2003018012          A1    20030123    US 2001-22511            20011213
    US 6706740             B2    20040316
    US 2003022902          A1    20030130    US 2001-22483            20011213
    US 2003022903          A1    20030130    US 2001-23497            20011213
    ZA 2002000435          A     20030117    ZA 2002-435              20020117
    US 2004034025          A1    20040219    US 2002-307844           20021202
    US 2004048864          A1    20040311    US 2002-307710           20021202
PRIORITY APPLN. INFO.:                       US 1999-149977P      P   19990820
                                             US 1999-150248P      P   19990823
```

US 2000-620662	A	20000720
US 1999-144676P	P	19990720
EP 2000-952599	A3	20000804
US 2000-632930	A3	20000804
WO 2000-US21523	W	20000804

OTHER SOURCE(S): MARPAT 134:207831
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; wherein X1-X4 independently = O, S, NR1, N, CR2, bond; R1 = H, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, OH, CHF2,C1-4 alkoxy; R2 = H, F, Cl, Br, CN, OH, C1-3 alkyl, C1-3 haloalkyl cyclopropyl, C1-3 alkoxy; Z = O, S, NOH, NOR3; R3 = C1-3 alkyl; A = C1-14 alkyl, C1-14 alkynyl, C1-14 cycloalkyl, aryl, heteroaryl, Q; M = H, Si(t-Bu)Me2, Si(Ph)Me2, SiEt3, CZR4, SO2R5; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; R5 = aryl, heteroaryl, C1-6 alkyl, C2-6 alkenyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl; X, Y independently = O, S; W = O, CH2, bond; R = C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, aryl, heteroaryl; R11 = H, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl; R10 = H, R, OR, OCOR, OCOOR; R8, R9 independently = H, C1-6 alkyl, C2-6 alkenyl; R6, R7 independently = H, C1-6 alkyl, C2-6 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl] are prepd. as fungicides involving application methods of effective usage of title compds. to control fungi, particularly plant pathogens and wood decaying fungi. The invention also encompasses hydrates, salts and complexes thereof. The title compd. II was prepd. and tested as fungicide.

IT **167173-87-7P 167173-88-8P 234112-92-6P**
321598-09-8P 321599-49-9P 321599-50-2P
321599-51-3P 321599-52-4P 321599-53-5P
321599-54-6P 321599-55-7P 321599-56-8P
321599-57-9P 321599-58-0P 321599-59-1P
321599-60-4P 321599-61-5P 321599-62-6P
321599-63-7P 321599-64-8P 321600-32-2P
321600-35-5P 321600-57-1P 321600-59-3P
321600-69-5P 321600-80-0P 321600-82-2P
321600-84-4P 321600-86-6P 321600-87-7P
321600-89-9P 321600-91-3P 321600-92-4P
321600-93-5P 321600-95-7P 321600-97-9P
321600-99-1P 321601-02-9P 321601-05-2P
321601-08-5P 321601-11-0P 321601-13-2P
321601-16-5P 321601-17-6P 321744-55-2P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 234112-92-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-6-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321598-09-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methyl-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-49-9 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-50-2 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-51-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-(acetyloxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-52-4 HCAPLUS
CN 3-Butenoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-53-5 HCAPLUS
CN Cyclopropanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-54-6 HCAPLUS
CN Propanoic acid, 2;2-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-55-7 HCAPLUS
CN Cyclopentanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-56-8 HCAPLUS
CN Cyclohexanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-57-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-(benzoyloxy)-9-methyl-2,6-dioxo-□ 7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-58-0 HCAPLUS
CN Benzeneacetic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-59-1 HCAPLUS
CN 2,6-Octadienoic acid, 3,7-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-□ methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□ 1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 321599-60-4 HCAPLUS
CN Tridecanoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-61-5 HCAPLUS
CN Octadecanoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-62-6 HCAPLUS
CN Carbamic acid, (1-methylethyl)-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-63-7 HCAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-□ methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□

1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-64-8 HCAPLUS
CN Carbonic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-32-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-ethoxy-3-hydroxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-35-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-hydroxy-4-(methylthio)-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-57-1 HCAPLUS
CN Cyclohexanecarboxylic acid, (3S,6S,7R,8R)-3-[[(6-bromo-3-hydroxy-4-methoxy-□ 2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-59-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-69-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-80-0 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-6-methyl-2-oxo-3-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-82-2 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-5-hydroxy-2-oxo-□ 3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-84-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-4,6-dimethyl-2-□ oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-86-6 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5-chloro-1,2-dihydro-6-□ methyl-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-□ (phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-87-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-□
pyridazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-89-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-3-□
oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-91-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-5,6-dimethyl-3-□
oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-92-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(6-chloro-3,4-dihydro-5-□ methoxy-3-oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□ 1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-93-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5,6-dichloro-3,4-dihydro-3-□ oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-95-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,4-dihydro-4-oxo-5-□ pyrimidinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-97-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,4-dihydro-2-methyl-4-oxo-5-□ pyrimidinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-99-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-8-□ (phenylmethyl)-3-[[(2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazin-6-□ yl)carbonyl]amino]-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-02-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[2,5-dihydro-3-(methylthio)-5-□ oxo-1,2,4-triazin-6-yl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□ 1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-05-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-□ isothiazolyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-08-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4,5-dihydro-4-oxo-1,2,5-□ thiadiazol-3-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-11-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5-hydroxy-1-methyl-1H-□ pyrazol-4-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-13-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(2,3-dihydro-1-methyl-3-oxo-□ 1H-pyrazol-4-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□ dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-16-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(2,3-dihydro-3-oxo-4-□
isoxazolyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-17-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-□
quinolinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321744-55-2 HCAPLUS
CN Cyclohexanecarboxylic acid, 2,6-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-□
methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□
1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **215798-10-0 321597-75-5 321601-40-5**
321601-47-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 215798-10-0 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-□(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321597-75-5 HCAPLUS
CN 1,5-Dioxonane-2,6-dione, 3-amino-9-methyl-8-(2-methylpropoxy)-7-□(phenylmethyl)-, (3S,7R,8R,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-40-5 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-amino-6-methyl-4,9-dioxo-8-□(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-47-2 HCAPLUS
CN 2-Pyridinecarboxamide, 6-bromo-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-□dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **321597-59-5P 321597-69-7P 321597-70-0P**
321597-71-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 321597-59-5 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,1-□
dimethylethoxy)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-□
dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-69-7 HCAPLUS
CN Cyclopropanecarboxylic acid, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-□
(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-70-0 HCAPLUS
CN Carbamic acid, (1-methylethyl)-, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-□
(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-71-1 HCAPLUS

CN Carbonic acid, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-(phenylmethoxy)-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **328255-60-3P 328255-61-4P 328255-64-7P**
328255-87-4P 328255-88-5P 328255-89-6P
328255-90-9P 328255-91-0P 328255-92-1P
328255-93-2P 328255-94-3P 328255-95-4P
328255-96-5P 328255-97-6P 328256-00-4P
328256-01-5P 328256-02-6P 328256-03-7P
328256-15-1P 328256-16-2P 328256-17-3P
328256-21-9P 328256-23-1P 328256-24-2P
328256-25-3P 328256-26-4P 328256-27-5P
328256-28-6P 328256-29-7P 328256-31-1P
328256-32-2P 328256-33-3P 328256-36-6P
328256-37-7P 328256-38-8P 328256-39-9P
328256-40-2P 328256-42-4P 328256-45-7P
328256-47-9P 328256-56-0P 328256-57-1P
328256-58-2P 328256-59-3P 328256-60-6P
328256-61-7P 328256-62-8P 328256-63-9P
328256-64-0P 328256-65-1P 328256-66-2P
328256-67-3P 328256-68-4P 328256-76-4P
328256-78-6P 328256-81-1P 328256-83-3P
328256-85-5P 328256-86-6P 328256-87-7P
328256-88-8P 328256-89-9P 328256-91-3P
328257-06-3P 328257-07-4P 328257-08-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of heterocyclic arom. amides as fungicides)

RN 328255-60-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-61-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(3-methoxy-1-oxopropoxy)-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-64-7 HCAPLUS
CN Propanoic acid, 2-methyl-, 4-methyl-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-87-4 HCAPLUS
CN 2-Pyridinecarboxamide, 3-(acetyloxy)-N-[(3S,7R,8R,9S)-8-(acetyloxy)-9-□ methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-88-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(1-oxopropoxy)-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-89-6 HCAPLUS

CN Butanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□ oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□ pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-90-9 HCAPLUS

CN 2-Butenoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□ oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□ pyridinyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 328255-91-0 HCAPLUS

CN Cyclopropanecarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-92-1 HCAPLUS
CN Propanoic acid, 2-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-93-2 HCAPLUS
CN 4-Pentenoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□
oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-94-3 HCAPLUS
CN Cyclobutanecarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-95-4 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-96-5 HCAPLUS
CN Butanoic acid, 3-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-97-6 HCAPLUS
CN 2-Butenoic acid, 3-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-00-4 HCAPLUS
CN Butanoic acid, 3,3-dimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-01-5 HCAPLUS
CN Cyclopentanecarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-02-6 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-03-7 HCAPLUS
CN Heptanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□
oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-15-1 HCAPLUS
CN Butanoic acid, 4-bromo-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-16-2 HCAPLUS
CN Hexanoic acid, 6-bromo-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-17-3 HCAPLUS
CN Benzoic acid, 2-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-21-9 HCAPLUS
CN Benzoic acid, 3,4-dimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-23-1 HCAPLUS
CN Benzoic acid, 4-methoxy-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-24-2 HCAPLUS
CN Benzoic acid, 4-(trichloromethoxy)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-□
8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-25-3 HCAPLUS
CN Benzoic acid, 2-fluoro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-26-4 HCAPLUS
CN Benzoic acid, 4-fluoro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-27-5 HCAPLUS
CN Benzoic acid, 2,4-difluoro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-28-6 HCAPLUS
CN Benzoic acid, 3,4-difluoro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-29-7 HCAPLUS
CN Benzoic acid, 3-(trifluoromethyl)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-□
8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-31-1 HCAPLUS
CN Benzoic acid, pentafluoro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-32-2 HCAPLUS
CN Benzoic acid, 2,4-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-33-3 HCAPLUS
CN Benzoic acid, 3,4-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-36-6 HCAPLUS
CN Benzoic acid, 2-bromo-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-37-7 HCAPLUS
CN Benzeneacetic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□ oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□ pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-38-8 HCAPLUS
CN Benzeneacetic acid, .alpha.-chloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-□ 8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-39-9 HCAPLUS
CN Benzenepropanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□ oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□ pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-40-2 HCAPLUS
CN 2-Propenoic acid, 3-phenyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 328256-42-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-□ [(methoxyacetyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□ (phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-45-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-□ [[(phenylmethoxy)acetyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-□ dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-47-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(3-methoxy-1-□

oxopropoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-56-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-chloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□
methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-57-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, 5,6-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□
methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-58-2 HCAPLUS
CN 3-Pyridinecarboxylic acid, 2,5-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□
methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-59-3 HCAPLUS
CN 4-Pyridinecarboxylic acid, 2-chloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□ methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-60-6 HCAPLUS
CN 2-Furancarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□ 1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□ 3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-61-7 HCAPLUS
CN 2-Thiophenecarboxylic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-62-8 HCAPLUS
CN 2-Thiopheneacetic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-63-9 HCAPLUS
CN 1,2,3-Thiadiazole-5-carboxylic acid, 4-methyl-, 4-methoxy-2-□
[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-□
(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI)
(CA INDEX NAME)□

Absolute stereochemistry.



RN 328256-64-0 HCAPLUS
CN 4-Isoxazolecarboxylic acid, 3-(2,6-dichlorophenyl)-5-methyl-,
4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-□
7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 328256-65-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(methoxycarbonyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-66-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(ethoxycarbonyl)oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-67-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(propoxycarbonyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-68-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(2-□ propenyloxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□ (phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-76-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[[[(1R,2S,5R)-5-□ methyl-2-(1-methylethyl)cyclohexyl]oxy]carbonyl]oxy]-2-□ pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-78-6 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(2-□ bromoethoxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-□ 4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-81-1 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-□ [[(phenylmethoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-□ dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-83-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[
[(phenoxycarbonyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-[
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[
[(propylthio)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-[
8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-86-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[
[(dimethylamino)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-[
methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 328256-87-7 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-4-methoxy-2-[

pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□
7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-88-8 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-4-methoxy-2-□
pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□
7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-89-9 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(3-methoxy-1-□
oxopropoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-91-3 HCAPLUS
CN Propanoic acid, 3-methoxy-, 4-methoxy-2-[[[(3S,7R,8R,9S)-8-(3-methoxy-1-□
oxopropoxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328257-06-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328257-07-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(methylsulfonyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328257-08-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(4-methylphenyl)sulfonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **167173-85-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic arom. amides as fungicides)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-□ pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-□ 7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **328255-98-7P 328255-99-8P 328256-04-8P**
328256-05-9P 328256-06-0P 328256-07-1P
328256-08-2P 328256-09-3P 328256-10-6P
328256-11-7P 328256-12-8P 328256-13-9P
328256-14-0P 328256-18-4P 328256-19-5P
328256-20-8P 328256-22-0P 328256-30-0P
328256-34-4P 328256-35-5P 328256-41-3P
328256-43-5P 328256-44-6P 328256-46-8P
328256-48-0P 328256-49-1P 328256-50-4P
328256-51-5P 328256-52-6P 328256-53-7P
328256-54-8P 328256-55-9P 328256-69-5P
328256-70-8P 328256-71-9P 328256-72-0P
328256-73-1P 328256-74-2P 328256-75-3P
328256-77-5P 328256-79-7P 328256-80-0P
328256-82-2P 328256-84-4P 328256-90-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterocyclic arom. amides as fungicides)
RN 328255-98-7 HCAPLUS
CN Pentanoic acid, 2-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328255-99-8 HCAPLUS
CN Butanoic acid, 2-ethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-04-8 HCAPLUS
CN Hexanoic acid, 2-ethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-05-9 HCAPLUS
CN Cyclopentanepropanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-06-0 HCAPLUS
CN Nonanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□

oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-07-1 HCAPLUS
CN Hexanoic acid, 3,5,5-trimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-□
(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-08-2 HCAPLUS
CN Undecanoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□
oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-09-3 HCAPLUS
CN 10-Undecenoic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□
oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-10-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(3-chloro-1-oxopropoxy)-4-□ methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□ 1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-11-7 HCAPLUS
CN Propanoic acid, 3-chloro-2,2-dimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□ methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-12-8 HCAPLUS
CN Butanoic acid, 4-chloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□ methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□ yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-13-9 HCAPLUS
CN 2-Propenoic acid, 2,3,3-trichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-□ 8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□

yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-14-0 HCAPLUS
CN Propanoic acid, 2-bromo-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-18-4 HCAPLUS
CN Benzoic acid, 3-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-19-5 HCAPLUS
CN Benzoic acid, 4-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-20-8 HCAPLUS
CN Benzoic acid, 4-propyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-22-0 HCAPLUS
CN Benzoic acid, 2,4,6-trimethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-30-0 HCAPLUS
CN Benzoic acid, 4-fluoro-2-(trifluoromethyl)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-□
9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-□
3-yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-34-4 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-35-5 HCAPLUS
CN Benzoic acid, 2,4,6-trichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-41-3 HCAPLUS
CN Benzeneacetic acid, .alpha.-ethyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-□
8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-43-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[(phenoxyacetyl)oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-44-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(phenylthio)acetyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-46-8 HCAPLUS
CN Benzeneacetic acid, .alpha.-methoxy-.alpha.-(trifluoromethyl)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-48-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(acetyloxy)acetyl]-4-□
methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□
1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-49-1 HCAPLUS
CN Propanoic acid, 2-(acetyloxy)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-□
methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-50-4 HCAPLUS
CN Propanoic acid, 2-(acetyloxy)-2-methyl-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□
methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-51-5 HCAPLUS
CN Propanedioic acid, phenyl-, mono[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-□
(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl] ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-52-6 HCAPLUS
CN Benzeneacetic acid, .alpha.-(acetyloxy)-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□
methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-53-7 HCAPLUS
CN Butanedioic acid, ethyl 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-□
1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-□
3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-54-8 HCAPLUS
CN Octanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-□
oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-□
pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-55-9 HCAPLUS
CN 2-Pyridinecarboxylic acid, 3,6-dichloro-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-□

methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-□
yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-69-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(butoxycarbonyl)oxy]-4-□
methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□
1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-70-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(3-□
butenyloxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-□
4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-71-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(2-□
butynyloxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-□
4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-72-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(2-□ methylpropoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-□ 8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-73-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(2,2-□ dimethylpropoxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-□ methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-74-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(hexyloxy)carbonyl]oxy]-□ 4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-□ 1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-75-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[[(2-□

ethylhexyl)oxy]carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-□
methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 328256-77-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(2-□
chloroethoxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-□
4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-79-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[(4-□
chlorobutoxy)carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-□
4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-80-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(2,2,2-□
trichloroethoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-□
dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328256-82-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[[[(2-□
chlorophenyl)methoxy]carbonyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-□
methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 328256-84-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(4-□
methylphenoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-□
8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



,b]-h]



RN 328256-90-2 HCAPLUS
CN Butanoic acid, 3,3-dimethyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(3-methoxy-1-□
oxopropoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-□
(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:63978 HCAPLUS
DOCUMENT NUMBER: 134:131431
TITLE: Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
INVENTOR(S): Ricks, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassam Salim; Miesel, John Louis; Fitzpatrick, Gina Marie; Meyer, Kevin Gerald; Niyaz, Noormohamed Mohamed; Morrison, Irene Mae; Gajewski, Robert Peter
PATENT ASSIGNEE(S): Dow Agrosciences LLC, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005769	A2	20010125	WO 2000-US19794	20000720
WO 2001005769	A3	20011122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2374995	AA	20010125	CA 2000-2374995	20000720
EP 1196388	A2	20020417	EP 2000-950470	20000720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003528806	T2	20030930	JP 2001-511430	20000720
BR 2000012615	A	20040330	BR 2000-12615	20000720
TR 200200587	T2	20041221	TR 2002-200200587	20000720
EP 1516874	A1	20050323	EP 2004-27006	20000720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1516875	A1	20050323	EP 2004-27015	20000720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AU 780698	B2	20050414	AU 2000-63572	20000720
US 6355660	B1	20020312	US 2000-632930	20000804
US 2002177578	A1	20021128	US 2001-22413	20011213
US 2003018052	A1	20030123	US 2001-22207	20011213

US 2003018012	A1	20030123	US 2001-22511		20011213
US 6706740	B2	20040316			
US 2003022902	A1	20030130	US 2001-22483		20011213
US 2003022903	A1	20030130	US 2001-23497		20011213
ZA 2002000436	A	20040302	ZA 2002-436		20020117
US 2004034025	A1	20040219	US 2002-307844		20021202
US 2004048864	A1	20040311	US 2002-307710		20021202
PRIORITY APPLN. INFO.:			US 1999-144676P	P	19990720
			US 1999-149977P	P	19990820
			US 1999-150248P	P	19990823
			EP 2000-950470	A3	20000720
			US 2000-620662	A3	20000720
			WO 2000-US19794	W	20000720
			US 2000-632930	A3	20000804

OTHER SOURCE(S): MARPAT 134:131431

GI



AB Title compds. I [W, X, Y, Z are selected from S, O, NR1, N, CR2 or bond and comprise a 5-6 membered (un)substituted heterocyclic ring; R1 = H, alkyl, alkenyl, alkynyl, OH, acyloxy, alkoxymethyl, CHF2, cyclopropyl, or alkoxy; R2 = H, halo, CN, OH, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, etc.; G = O, S or NOR3 where R3 = H or alkyl; A = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, unsatd. cycloalkyl, heterocycle, bi or tricyclic ring system which may contain heteroatoms, aryl or heteroaryl, etc.] bearing a hydroxy group adjacent to the amide functionality are prepd. and disclosed as antifungal agents, particularly for plants. Thus, pyridinyl carboxamide II was prepd. via amidation of 3-benzyloxy-6-bromo-4-methoxypyridin-2-carbonyl chloride with 4-(4-trifluoromethylphenoxy)aniline with subsequent deprotection. The preferred fungicidal compn. consists of a compd. of formula I with a phytol. acceptable carrier. Activity has been demonstrated against a variety of fungi, e.g., Plasmopara viticola (Downy Mildew of Grape), Phytophthora infestans (Late Blight of Tomato), and Venturia inaequalis (Apple Scab). I is both useful for eradication and prevention of fungal attack.

IT **167173-87-7P 167173-88-8P 234112-79-9P**
234112-92-6P 321598-09-8P 321599-49-9P
321599-50-2P 321599-51-3P 321599-52-4P
321599-53-5P 321599-54-6P 321599-55-7P
321599-56-8P 321599-57-9P 321599-58-0P
321599-59-1P 321599-60-4P 321599-61-5P
321599-62-6P 321599-63-7P 321599-64-8P
321600-32-2P 321600-35-5P 321600-57-1P
321600-59-3P 321600-69-5P 321600-80-0P
321600-82-2P 321600-84-4P 321600-86-6P
321600-87-7P 321600-89-9P 321600-91-3P
321600-92-4P 321600-93-5P 321600-95-7P

321600-97-9P 321600-99-1P 321601-02-9P
321601-05-2P 321601-08-5P 321601-11-0P
321601-13-2P 321601-16-5P 321601-17-6P
321744-55-2P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 234112-79-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-92-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-6-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-

7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321598-09-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methyl-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-49-9 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-50-2 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(3S,7R,8R,9S)-9-methyl-8-(2-methylpropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-51-3 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-(acetyloxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-52-4 HCAPLUS
CN 3-Butenoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-53-5 HCAPLUS
CN Cyclopropanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-54-6 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-55-7 HCAPLUS

CN Cyclopentanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-56-8 HCAPLUS

CN Cyclohexanecarboxylic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-57-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(3S,7R,8R,9S)-8-(benzoyloxy)-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-58-0 HCAPLUS
CN Benzeneacetic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-59-1 HCAPLUS
CN 2,6-Octadienoic acid, 3,7-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 321599-60-4 HCAPLUS
CN Tridecanoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-61-5 HCAPLUS
CN Octadecanoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-

pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-62-6 HCAPLUS

CN Carbamic acid, (1-methylethyl)-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-63-7 HCAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321599-64-8 HCAPLUS

CN Carbonic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-32-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-ethoxy-3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-35-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-hydroxy-4-(methylthio)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-57-1 HCAPLUS
CN Cyclohexanecarboxylic acid, (3S,6S,7R,8R)-3-[[(6-bromo-3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-59-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-69-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-80-0 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-82-2 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-5-hydroxy-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-84-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-86-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5-chloro-1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-87-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-pyridazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-89-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-3-oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-91-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-5,6-dimethyl-3-oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-92-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(6-chloro-3,4-dihydro-5-methoxy-3-oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-93-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5,6-dichloro-3,4-dihydro-3-oxopyrazinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-95-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,4-dihydro-4-oxo-5-pyrimidinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-97-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,4-dihydro-2-methyl-4-oxo-5-pyrimidinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321600-99-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-8-(phenylmethyl)-3-[[(2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazin-6-yl)carbonyl]amino]-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-02-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[2,5-dihydro-3-(methylthio)-5-oxo-1,2,4-triazin-6-yl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-05-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4-hydroxy-3-isothiazolyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-08-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(4,5-dihydro-4-oxo-1,2,5-thiadiazol-3-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-11-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(5-hydroxy-1-methyl-1H-pyrazol-4-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-13-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(2,3-dihydro-1-methyl-3-oxo-1H-pyrazol-4-yl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-16-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(2,3-dihydro-3-oxo-4-isoxazolyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-17-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-quinolinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321744-55-2 HCAPLUS
CN Cyclohexanecarboxylic acid, 2,6-dimethyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 215798-10-0 321597-75-5 321601-40-5
321601-47-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and fungicidal activity of heterocyclic arom. amides)
RN 215798-10-0 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321597-75-5 HCAPLUS
CN 1,5-Dioxonane-2,6-dione, 3-amino-9-methyl-8-(2-methylpropoxy)-7-(phenylmethyl)-, (3S,7R,8R,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-40-5 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321601-47-2 HCAPLUS
CN 2-Pyridinecarboxamide, 6-bromo-N-[(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-4-methoxy-3-(phenylmethoxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **321597-59-5P 321597-69-7P 321597-70-0P 321597-71-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 321597-59-5 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-69-7 HCAPLUS
CN Cyclopropanecarboxylic acid, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-70-0 HCAPLUS
CN Carbamic acid, (1-methylethyl)-, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321597-71-1 HCAPLUS
CN Carbonic acid, (3S,6S,7R,8R)-3-[[[6-bromo-4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:574605 HCAPLUS
DOCUMENT NUMBER: 131:297409
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 V. Inhibition mechanism of bovine heart mitochondrial cytochrome bc1 by the novel antibiotic UK-2A
AUTHOR(S): Machida, Kiyotaka; Takimoto, Hiroaki; Miyoshi, Hideto; Taniguchi, Makoto
CORPORATE SOURCE: Department of Biology, Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (1999), 52(8), 748-753
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A is a potent antifungal antibiotic isolated from Streptomyces sp. 517-02 and its structure is highly similar to that of antimycin A. The authors investigated the inhibition mechanism of bovine heart mitochondrial cytochrome bc1 complex by the UK-2A using antimycin A and myxothiazol as the ref. inhibitors of ubiquinol oxidn. (Qo) and ubiquinone redn. (Qi) sites, resp. The inhibitory potency of UK-2A was about 3-fold less than antimycin A. On the basis of the effects of UK-2A on the redn. kinetics of b and c1 hemes, this compd. appeared to be an inhibitor of the Qi site. However, since spectral changes of dithionite-reduced cytochrome b induced by UK-2A binding differed from that of antimycin A, the precise binding manner of UK-2A to the enzyme is not identical to that of antimycin A. It could be concluded that antimycin A binding to cytochrome b is primarily decided by structural specificity of the salicylic acid moiety.

IT **167173-85-5**, Antibiotic UK-2A **167173-86-6**, Antibiotic UK-2B **167173-87-7**, Antibiotic UK-2C **167173-88-8**, Antibiotic UK-2D
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(UK-2A, B, C and D as novel antifungal antibiotics from Streptomyces)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS
CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:511149 HCAPLUS
DOCUMENT NUMBER: 131:129825
TITLE: Novel antifungal compounds and process for producing the same
INVENTOR(S): Sakanaka, Osamu; Teraoka, Takeshi; Mitomo, Koichi; Tamura, Takayoshi; Murai, Yasushi; Iinuma, Katsuharu; Kuzuhara, Kikuko; Mikoshiba, Haruki; Taniguchi, Makoto
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940081	A1	19990812	WO 1999-JP541	19990208
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319807	AA	19990812	CA 1999-2319807	19990208
AU 9924398	A1	19990823	AU 1999-24398	19990208
AU 751098	B2	20020808		
EP 1054011	A1	20001122	EP 1999-903901	19990208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 506249	A	20030429	NZ 1999-506249	19990208
PRIORITY APPLN. INFO.:			JP 1998-26257 A	19980206
			WO 1999-JP541 W	19990208

OTHER SOURCE(S): MARPAT 131:129825
GI



I

AB The title compds. [I; R1 = iso-Bu, tigloyl, isovaleryl, 2-methylbutanoyl; R2 = H, arom. acyl, protecting group such substituted benzoyl, substituted nicotinoyl; R3 = H, nitro, amino, acylamino, N,N-dialkylamino; with provisos] are prepd. Thus, UK-2A in CH2Cl2 contg. pyridine and PCl5 was refluxed for 1.5 h, the reaction mixt. was allowed to cool and then

reacted with methanol for 15 h to give (2R,3R,4S,7S)-7-amino-2-benzyl-5,9-dioxa-3-isobutyryloxy-4-methyl-1,6-cyclononanedione. In an antifungal test, (2R,3R,4S,7S)-7-(2-hydroxynicotinylamino)-2-benzyl-5,9-dioxa-3-isobutyryl-4-methyl-1,6-cyclononanedione (also prepd.) at 0.05 μg showed potency almost double that of UK-2A against Saccharomyces cerevisiae.

IT **234112-85-7P 234112-86-8P 234112-88-0P**
234112-89-1P 234112-90-4P 234113-05-4P
234113-06-5P 234113-14-5P 234113-15-6P
234113-16-7P 234113-17-8P 234113-21-4P
234113-26-9P 234113-27-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of UK-2A derivs. as antifungals)

RN 234112-85-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4,6-dimethoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-86-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4,5-dimethoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-88-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4,5-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-89-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-90-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-1-oxido-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-05-4 HCAPLUS
CN Heptanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-06-5 HCAPLUS
CN Decanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-

pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-14-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-nitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-15-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(3-amino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-16-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-5-nitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-17-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(5-amino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-21-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3,5-dinitrobenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-26-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-8-[(4-nitrophenyl)methyl]-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-27-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[(4-aminophenyl)methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **210300-07-5P 215798-04-2P 215798-05-3P**
234112-77-7P 234112-78-8P 234112-79-9P
234112-80-2P 234112-81-3P 234112-82-4P
234112-83-5P 234112-84-6P 234112-87-9P
234112-91-5P 234112-92-6P 234112-93-7P
234112-94-8P 234112-95-9P 234112-96-0P
234112-97-1P 234112-98-2P 234112-99-3P
234113-00-9P 234113-01-0P 234113-02-1P
234113-03-2P 234113-04-3P 234113-07-6P
234113-08-7P 234113-09-8P 234113-10-1P
234113-11-2P 234113-12-3P 234113-13-4P
234113-18-9P 234113-19-0P 234113-20-3P
234113-22-5P 234113-23-6P 234113-24-7P
234113-25-8P 234113-28-1P 234113-29-2P
234113-30-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of UK-2A derivs. as antifungals)

RN 210300-07-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-05-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 234112-77-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 210300-07-5
CMF C19 H25 N O6

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 234112-78-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-3-[[(phenylmethoxy)carbonyl]amino]-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-79-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,2-dihydro-2-oxo-3-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-80-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,6-dihydro-6-oxo-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-81-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-6-methyl-4,9-dioxo-8-(phenylmethyl)-3-[[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)carbonyl]amino]-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-82-4 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-methyl-4-quinolinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-83-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3,4-dihydro-3-oxo-2-quinoxalinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-84-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,6-dihydro-3-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-87-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4,6-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-91-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[6-(acetyloxy)-4-methoxy-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-92-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-6-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-93-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-94-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-(benzoyloxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-95-9 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[4-methoxy-3-[[(1-methylethoxy)carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-96-0 HCAPLUS
CN Butanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-97-1 HCAPLUS
CN Butanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-98-2 HCAPLUS
CN Pentanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234112-99-3 HCAPLUS
CN Hexanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-00-9 HCAPLUS
CN Heptanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-01-0 HCAPLUS
CN Nonanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-02-1 HCAPLUS
CN Decanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-

pyridinyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-03-2 HCAPLUS
CN Pentanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-04-3 HCAPLUS
CN Hexanedioic acid, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-07-6 HCAPLUS
CN Pentanedioic acid, butyl 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-08-7 HCAPLUS
CN Heptanedioic acid, mono[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-09-8 HCAPLUS
CN Decanedioic acid, mono[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-10-1 HCAPLUS
CN Alanine, N-[(phenylmethoxy)carbonyl]-, 4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-11-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-

[[bis(phenylmethoxy)phosphinyl]oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-12-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[3-[(diethoxyphosphinyl)oxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-13-4 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-18-9 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(4-chloro-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-19-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(5-chloro-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-20-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-4-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-22-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(dimethylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-23-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[5-(dimethylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-24-7 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(3,5-diamino-2-hydroxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-25-8 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[5-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-28-1 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[[4-(formylamino)phenyl]methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-29-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-8-[[4-(dimethylamino)phenyl]methyl]-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234113-30-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[[1,6-dihydro-4-methoxy-6-oxo-3-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **167173-85-5**, (+)-UK-2A
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of UK-2A derivs. as antifungals)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:368241 HCAPLUS
DOCUMENT NUMBER: 131:125082
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02: IV. Comparative studies of UK-2A with antimycin A3 on cytotoxic activity and reactive oxygen species generation in LLC-PK1 cells
AUTHOR(S): Takimoto, Hiroaki; Machida, Kiyotaka; Ueki, Masashi; Tanaka, Toshio; Taniguchi, Makoto
CORPORATE SOURCE: Department of Biology, Graduate School of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (1999), 52(5), 480-484
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A, a novel antifungal antibiotic, is a structural relative of antimycin A3 (AA) and its mode of action is similar to that of AA which inhibits mitochondrial electron transport at complex III. In spite of their structural resemblance, AA had strong cytotoxicity while UK-2A had little cytotoxicity against LLC-PK1 cells as well as other types of cultured cells. When cells were treated with UK-2A or with AA the intracellular ATP content decreased significantly within 5 min in glucose-free medium to almost the same extent in both cases. Moreover, under the same conditions, UK-2A killed cells at a similar rate to AA. This suggested that UK-2A entered into the cells and, like AA, inhibited mitochondrial electron transport. On the other hand, AA stimulated reactive oxygen species (ROS) prodn. within 5 min even at a low concn. of 1 μM whereas UK-2A did not show such an effect. The difference in the ROS-producing abilities of UK-2A and AA may account for the different cytotoxic effects of the two compds.

IT **167173-85-5**, UK-2A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparative studies of UK-2A with antimycin A3 on cytotoxic activity and reactive oxygen species generation in LLC-PK1 cells)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:313243 HCAPLUS
DOCUMENT NUMBER: 131:214101
TITLE: Total synthesis of the antifungal dilactone UK-2A and analogs and their bioactivities
AUTHOR(S): Kamei, Noriyuki; Shibata, Tetsuo; Inoguchi, Kiyoshi; Senda, Hisato; Ikari, Takashi; Itoh, Nobuko; Shimano, Masanao
CORPORATE SOURCE: Department of Medical Chemistry and Molecular Design, Drug Discovery Research Laboratories, Kaken Pharmaceutical Co., Ltd., Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1998), 40th, 679-684
CODEN: TYKYDS
PUBLISHER: Nippon Kagakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



AB UK-2A (I) which has recently been isolated from the mycelial cake of Streptomyces sp. 517-02, possesses nine-membered dilactone and a picolinic acid moiety. The plane structure of UK-2A has been elucidated by 1H and 13C NMR analyses and chem. degrdn. studies, but the relative and abs. configurations of the four chiral centers in UK-2A still remain to be detd. UK-2A has strongly inhibited the growth of various kinds of yeasts and filamentous fungi, but its cytotoxic activities against several kinds of mammalian cells were very weak. The combination of its interesting mol. architecture and the potent antifungal activity prompted us to launch the total synthesis of UK-2A. The synthesis of UK-2A has been achieved

through a 12-step sequence from II in 26% overall yield. The key strategy employed in this approach involves; (1) construction of the three consecutive chiral centers from C2 to C4 based upon the well-established Evans aldol reaction and (2) the nine-membered lactonization. The authors' synthetic route to UK-2A would permit a practical and reliable construction of UK-2A and a variety of its analogs. In order to define the selective cytotoxicities of UK-2A against yeasts and filamentous fungi, UK-2A and its analogs synthesized were subjected to the MIC evaluation and cytotoxic activity examn. compared with the ref. compds., amphotericin B and fluconazole. UK-2A has a broad antifungal spectrum, while its cytotoxicities was considerably weak compared to other substrates. The results of the UK-2A analogs suggested that the basicity of the picolinic acid moiety in UK-2A was essential for the antifungal activities and that the feature of the nine-membered dilactone contributed to the selective cytotoxicities.

IT **167173-85-5P**, Antibiotic UK 2A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(total synthesis of antifungal dilactone UK-2A and analogs and bioactivities)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **194931-82-3P 210426-79-2P 215798-04-2P 215798-05-3P 215798-17-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(total synthesis of antifungal dilactone UK-2A and analogs and bioactivities)

RN 194931-82-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210426-79-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-04-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-05-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-17-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 210300-07-5P 210300-13-3P 210300-18-8P
215798-00-8P 215798-10-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total synthesis of antifungal dilactone UK-2A and analogs and bioactivities)
RN 210300-07-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210300-13-3 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210300-18-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-00-8 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-10-0 HCAPLUS

CN Carbamic acid, [(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:184083 HCAPLUS
DOCUMENT NUMBER: 130:193104
TITLE: Rice blast controlling agents and wheat scab controlling agents
INVENTOR(S): Teraoka, Takeshi; Kuzuhara, Kikuko; Mikoshiba, Haruki; Matsumoto, Kuniomi; Iinuma, Katsuharu; Futamura, Takafumi; Yasutake, Tetsuya; Sakanaka, Osamu; Mitomo, Koichi; Taniguchi, Makoto
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911127	A1	19990311	WO 1998-JP3876	19980831

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9888878	A1	19990322	AU 1998-88878	19980831
EP 1013169	A1	20000628	EP 1998-940634	19980831

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:	JP 1997-233658	A	19970829
	WO 1998-JP3876	W	19980831

OTHER SOURCE(S): MARPAT 130:193104

GI



AB These agents contain a compd. represented by formula (I) in which R1 represents alkyl or alkenyl and R2 represents hydrogen or methoxy. The compd. is highly effective in preventing rice blast and wheat scab and is not injurious to the plants. Specific compds. used in the examples are obtained by the method described in a publication presented earlier. Activities of I where R1 = iso-Pr and R2 = H (1), R1 = iso-Pr and R2 = OMe (2), R1 = (Z)-2-butenyl and R2 = OMe (3), R1 = iso-Bu and R2 = OMe (4), and R1 = sec-Bu and R2 = OMe (5), were demonstrated.

IT **167173-87-7 167173-88-8 220766-86-9 220766-87-0 220827-77-0**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(as rice blast controlling agents and wheat scab controlling agents)

RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS

CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 220766-86-9 HCAPLUS
CN Propanoic acid, 2-methyl-, 3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)



RN 220766-87-0 HCAPLUS
CN Propanoic acid, 2-methyl-, 3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)



RN 220827-77-0 HCAPLUS
CN 3-Pentenoic acid, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:19692 HCAPLUS
DOCUMENT NUMBER: 130:168617
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02 III. Absolute configuration of an antifungal antibiotic, UK-2A, and consideration of its conformation
AUTHOR(S): Shibata, Kozo; Hanafi, Muhammad; Fujii, Jyunko; Sakanaka, Osamu; Iinuma, Katsuharu; Ueki, Masashi; Taniguchi, Makoto
CORPORATE SOURCE: Faculty of Science, Osaka City University, Osaka, 558-8585, Japan
SOURCE: Journal of Antibiotics (1998), 51(12), 1113-1116
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The abs. configuration of UK-2A (I) was detd. by the elucidation of the abs. configurations of butanolide II and the serine deriv. III, the products of alk. hydrolysis of I. The abs. configuration of UK-2A was found to be (+)-(2R,3R,4S,7S).

IT **167173-86-6**, UK 2B **167173-87-7**, UK 2C
167173-88-8, UK 2D
RL: MSC (Miscellaneous)
(detn. of the abs. configuration of UK-2A, an antifungal antibiotic)

RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



IT 167173-85-5
RL: PRP (Properties)
(detn. of the abs. configuration of UK-2A, an antifungal antibiotic)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:651994 HCAPLUS
DOCUMENT NUMBER: 130:3703
TITLE: Total synthesis of the antifungal dilactones UK-2A and UK-3A: the determination of their relative and absolute configurations, analog synthesis and antifungal activities
AUTHOR(S): Shimano, Masanao; Kamei, Noriyuki; Shibata, Tetsuo; Inoguchi, Kiyoshi; Itoh, Nobuko; Ikari, Takashi; Senda, Hisato
CORPORATE SOURCE: Dep. Med. Chem. Mol. Design, Drug Discovery Res. Lab., Kaken Pharmaceutical Co., Ltd., Minami Kawara-cho, Yamashina-ku, Kyoto, 607-8042, Japan
SOURCE: Tetrahedron (1998), 54(42), 12745-12774
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:3703
GI



I

AB The synthesis of the antifungal dilactones (I), UK-2A (R = OMe) and UK-3A (R = H), is described. In addn. to providing a workable synthetic route to these potent antifungal antibiotics, this has allowed us to det. the assignment of the relative and abs. configurations in the nine-membered ring. Furthermore, UK-2A analogs were also synthesized and evaluated for their antifungal activities and cytotoxic activities along with UK-2A, (2R, 3R, 4S, 7R)-UK-2A, UK-3A, (2R, 3R, 4S, 7R)-UK-3A, and antimycin A. The structural requirements for the selective cytotoxicity against yeasts and filamentous fungi will also be suggested.

IT **167173-85-5P**, UK-2A **194931-82-3P**, UK-3A **210426-79-2P** **215798-04-2P** **215798-05-3P** **215798-17-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis, antifungal activity, cytotoxicity and abs. configuration of

dilactones UK-2A and UK-3A)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 194931-82-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210426-79-2 HCAPLUS

CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-04-2 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[3-(formylamino)-2-hydroxybenzoyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-05-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[(2-hydroxy-3-methoxybenzoyl)amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-17-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **210300-07-5P 210300-13-3P 210300-17-7P**
210300-18-8P 215798-00-8P 215798-10-0P
215798-15-5P 215798-16-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, antifungal activity, cytotoxicity and abs. configuration of dilactones UK-2A and UK-3A)
RN 210300-07-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210300-13-3 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210300-17-7 HCAPLUS
CN Carbamic acid, [(3R,7R,8R,9S)-8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210300-18-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215798-00-8 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-10-0 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-15-5 HCAPLUS
CN Carbamic acid, [(3R,7R,8R,9S)-8-hydroxy-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215798-16-6 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:355895 HCAPLUS
DOCUMENT NUMBER: 129:122477
TITLE: Enantioselective total synthesis of the antifungal dilactone, UK-2A: the determination of the relative and absolute configurations
AUTHOR(S): Shimano, Masanao; Shibata, Tetsuo; Kamei, Noriyuki
CORPORATE SOURCE: Dep. Medicinal Chem. Molecular Design, Drug Discovery Res. Labs., Kaken Pharmaceutical Co., Kyoto, 607-8042, Japan
SOURCE: Tetrahedron Letters (1998), 39(24), 4363-4366
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:122477
GI



I

AB The synthesis of the antifungal dilactone, UK-2A (I), is described. In addn. to providing a workable synthetic route to this potent antifungal antibiotic, this has allowed us to det. the assignment of the relative and abs. configurations in the nine-membered ring.

IT **167173-85-5P**, (+)-UK-2A **210426-79-2P**, 7-epi-UK-2A
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(abs. configuration of UK-2A via enantioselective total synthesis)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210426-79-2 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **210300-07-5P 210300-13-3P 210300-17-7P 210300-18-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(abs. configuration of UK-2A via enantioselective total synthesis)
RN 210300-07-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210300-13-3 HCAPLUS
CN Carbamic acid, [(3S,7R,8R,9S)-8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210300-17-7 HCAPLUS
CN Carbamic acid, [(3R,7R,8R,9S)-8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9-methyl-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 210300-18-8 HCAPLUS

CN Propanoic acid, 2-methyl-, (3R,6S,7R,9R)-3-amino-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:22846 HCAPLUS
DOCUMENT NUMBER: 128:163891
TITLE: The mode of action of UK-2A and UK-3A, novel antifungal antibiotics from Streptomyces sp. 517-02
AUTHOR(S): Ueki, Masashi; Taniguchi, Makoto
CORPORATE SOURCE: Dep. Biology, Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1997), 50(12), 1052-1057
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A and UK-3A are structural relatives of antimycins, which were isolated as antifungal antibiotics with little cytotoxicity that demonstrated inhibition of respiratory activity. They halve the cellular respiration of yeast within 4~5 min and the intracellular ATP content within 2~5 min. They inhibited the yeast mitochondrial respiration using β-hydroxybutyrate and succinate as a respiratory substrate, but no inhibition was obsd. using ascorbate-reduced tetra-Me p-phenylenediamine as the substrate. The site of respiratory inhibition of UK-2A and UK-3A was thought to be the cytochrome bc1 complex in the mitochondrial electron transport chain of yeast cells. They also inhibited the mitochondrial respiration of rat liver. Intact animal cells might have some system to defend themselves from the actions of UK-2A and UK-3A.

IT **167173-85-5**, UK-2A **194931-82-3**, Antibiotic UK-3A
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(mechanism of antifungal action of UK-2A and UK-3A)

RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 194931-82-3 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:504110 HCAPLUS
DOCUMENT NUMBER: 127:217524
TITLE: UK-3A, a novel antifungal antibiotic from Streptomyces sp. 517-02: fermentation, isolation, structural elucidation and biological properties
AUTHOR(S): Ueki, Masashi; Kusumoto, Atsushi; Hanafi, Muhammad; Shibata, Kozo; Tanaka, Toshio; Taniguchi, Makoto
CORPORATE SOURCE: Faculty of Science, Osaka City University, Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1997), 50(7), 551-555
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A novel antifungal antibiotic, UK-3A (I), was obtained from the mycelial cake of Streptomyces sp. 517-02. I was very similar in structure to UK-2A, a structural relative of antimycin A. The antifungal spectrum of I was relatively broad (MICs for yeasts and filamentous fungi: 1.56~6.25 and 0.39~1.56 μg/mL, resp.). The cytotoxic activity of I was weak (IC50: 18~100 μg/mL).

IT **194931-82-3P**, Antibiotic UK 3A
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(UK-3A is a novel antifungal antibiotic from Streptomyces)

RN 194931-82-3 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1997:16443 HCAPLUS
DOCUMENT NUMBER: 126:144017
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. II. Structural elucidation
AUTHOR(S): Hanafi, Muhammad; Shibata, Kozo; Ueki, Masashi; Taniguchi, Makoto
CORPORATE SOURCE: Fac. Sci., Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1996), 49(12), 1226-1231
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB UK-2A, UK-2B, UK-2C and UK-2D, novel antibiotics produced by Streptomyces sp. 517-02, exhibit strong antifungal activity. The structures were elucidated based on spectral and chem. evidence that these compds. are the derivs. of the nine-membered dilactone formed from serine and 4-hydroxypentanoic acid moiety.

IT **167173-86-6P** **167173-87-7P**, UK 2C **167173-88-8P**, UK 2D
RL: PRP (Properties); PUR (Purification or recovery); PREP (Preparation)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)

RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS
CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



IT **167173-85-5P**
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)
RN 167173-85-5 HCAPLUS
CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **186528-19-8P**, O-Methyl UK 2A
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(structural elucidation of UK-2A, UK-2B, UK-2C and UK-2D, novel antifungal antibiotics from Streptomyces sp. 517-02)
RN 186528-19-8 HCAPLUS
CN Propanoic acid, 2-methyl-, 3-[[(3,4-dimethoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, [3S-(3R*,6R*,7S*,8S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:463922 HCAPLUS
DOCUMENT NUMBER: 125:109869
TITLE: UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. I. Fermentation, isolation, and biological properties
AUTHOR(S): Ueki, Masahi; Abe, Keiichi; Hanafi, Muhammad; Shibata, Kozo; Tanaka, Toshio; Taniguchi, Makoto
CORPORATE SOURCE: Fac. Science, Osaka City Univ., Osaka, 558, Japan
SOURCE: Journal of Antibiotics (1996), 49(7), 639-643
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Novel antifungal antibiotics, UK-2A (I), UK-2B (II) and a mixt. of UK-2C and UK-2D, were obtained from the mycelial cake of Streptomyces sp. 517-02. All of the UK-2 compds. were similar in structure to antimycin A. The antifungal activities of of UK-2 compds. were as strong as that of antimycin A. However, the UK-2 compds. demonstrated weak cytotoxicity compared to antimycin A.

IT **167173-85-5**, UK 2A **167173-86-6**, UK 2B
167173-87-7, UK 2C **167173-88-8**, UK 2D
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. I. Fermn., isolation, and biol. properties)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



L7 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:934118 HCAPLUS
DOCUMENT NUMBER: 123:337552
TITLE: Fungicides manufacture with Streptoverticillium
INVENTOR(S): Taniguchi, Makoto; Shibata, Kozo; Abe, Keiichi; Kodama, Tooru; Uotani, Kazumichi; Oonishi, Yoshitaka
PATENT ASSIGNEE(S): Suntory Ltd., Japan; Meiji Seika Co.; Meiji Seika Kaisha, Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07233165	A2	19950905	JP 1994-26884	19940224
JP 3526602	B2	20040517		
PRIORITY APPLN. INFO.:			JP 1994-26884	19940224

OTHER SOURCE(S): MARPAT 123:337552
GI



I

AB Fungicides (I: R = linear or branched aliph. (un)satd. acyl group) are manufd. by culturing Streptoverticillium sp. SAM2084. Shake-culture of Streptoverticillium sp. SAM2084 for manuf. of four I wherein R = 2-methylpropanoyl (UK-2A), trans-2-methyl-2-butenoyl (UK-2B), 3-methylbutanoyl (UK-2C), and 2-methylbutanoyl (UK-2D) was shown. Also given were the physiol. and morphol. characteristics of the Streptoverticillium sp. SAM2084.

IT **167173-85-5P**, UK 2A **167173-86-6P**, UK 2B
167173-87-7P, UK 2C **167173-88-8P**, UK 2D
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fungicides manuf. with Streptoverticillium)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS
CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



L7 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:671786 HCAPLUS
DOCUMENT NUMBER: 123:164736
TITLE: The structures of UK-1 and UK-2, novel antibiotics from Streptomyces sp. 517-02
AUTHOR(S): Hanafi, O Muhammad; Kozo, Shibata; Masaru, Kashiwada; Masashi, Ueki; Makoto, Taniguchi
CORPORATE SOURCE: Faculty Science, Osaka City University, Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1994), 36th, 728-35
CODEN: TYKYDS
PUBLISHER: Nippon Kagakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The mycelial cake was extd. with acetone, and filtered. The filtrate was concd. to give aq. soln., which was extd. with chloroform. Org. layer was concd. to yield an oily material, followed by purifn. on silica gel column chromatog. to give crude UK-1 and UK-2. Finally, the recrystn. of each fractions from MeOH, afforded UK-1 and UK-2. UK-1 (I), a novel metabolite, demonstrated potent cytotoxic activity against B16, Hela and P388 cells, and UK-2, novel complex of antibiotics, exhibited strong antifungal activity. Methylation of UK-1 by CH3I and anhyd. K2CO3 in dry acetone gave monomethyl ether deriv., Me-UK-1. Alk. hydrolysis of UK-1 afforded carboxylic acid deriv., DeMe-UK-1. Partial structures, A, B, and C were elucidated by COSY, and COLOC expts. Based on these results, the structure of UK-1 was deduced to be a novel benzoxazole dimer deriv. UK-2, novel metabolite contg. complex of antibiotics with strong antifungal activity, was purified by reverse phase HPLC, to give UK-2A, B, C and D. From NMR and mass spectral data, the structures of UK-2A, B, C and D were established as isobutyrate, tiglate, isovalerate, and 2-methylbutyrate of nine membered dilactone skeleton, resp. Based on the

result of synthesis of hydrolysis products, the abs. configuration of UK-2 was identified.

IT **167173-85-5**, Antibiotic UK 2A **167173-86-6**, Antibiotic UK 2B **167173-87-7**, Antibiotic UK 2C **167173-88-8**, Antibiotic UK 2D
RL: PRP (Properties)
(structures of UK-1 and UK-2, novel antibiotics from Streptomyces sp. 517-02)

RN 167173-85-5 HCAPLUS

CN Propanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167173-86-6 HCAPLUS

CN 2-Butenoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 167173-87-7 HCAPLUS

CN Butanoic acid, 3-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167173-88-8 HCAPLUS

CN Butanoic acid, 2-methyl-, (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-

7-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	125.87	455.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.79	-16.79

FILE 'CAOLD' ENTERED AT 09:56:32 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 09:46:59 ON 13 JUN 2005)

FILE 'REGISTRY' ENTERED AT 09:47:05 ON 13 JUN 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 16 S L4
L6 322 S L4 FULL

FILE 'HCAPLUS' ENTERED AT 09:53:19 ON 13 JUN 2005
L7 23 S L6

```
     FILE 'REGISTRY' ENTERED AT 09:53:26 ON 13 JUN 2005

     FILE 'HCAPLUS' ENTERED AT 09:53:35 ON 13 JUN 2005

     FILE 'CAOLD' ENTERED AT 09:56:32 ON 13 JUN 2005

=> s l6
L8            0 L6

=>
```